Pyrimidine fused ring derivative as well as preparation method and application thereof

CN118900836APending Publication Date: 2024-11-05ZHEJIANG HISUN PHARMA CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380027044.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-27
Filing Date
2023-04-25
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

Existing HPK1 inhibitors have insufficient safety and efficacy when treating tumors, resulting in increased risks and increased patient pain during treatment.

Method used

A compound of general formula or its stereoisomer, tautomer or pharmaceutically acceptable salt was developed, which is used to prepare HPK1 inhibitors through specific structural composition and synthesis methods, including specific ring A, Ring B, group selection and linkage methods to form compounds with potential pharmacological properties.

Benefits of technology

The compound shows significant inhibitory activity against HPK1 kinase, can effectively reduce the phosphorylation of p-SLP76 S376 in Jurkat cells and enhance the activation ability of IL2 release, providing a safer and more effective treatment for tumors and inflammatory reactions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118900836A_ABST
    Figure CN118900836A_ABST
Patent Text Reader

Abstract

Relates to a substituted pyrimidine ring derivative, a preparation method thereof and application of a pharmaceutical composition containing the derivative in medicine. Specifically, the invention relates to a substituted pyrimidine ring derivative as shown in a general formula (I), a preparation method and medicinal salts thereof, and application of the substituted pyrimidine ring derivative and the medicinal salts thereof as therapeutic agents, especially HPK1 inhibitors, and definition of each substituent in the general formula (I) is the same as that in the specification. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Pyrimidocyclic derivatives and their preparation methods and uses Technical Field

[0001] The present invention relates to a pyrimidocyclic derivative, a preparation method thereof, a pharmaceutical composition containing the derivative, and use of the derivative as a therapeutic agent, in particular as an HPK1 inhibitor. Background Art

[0002] Hematopoietic progenitor cell kinase (HPK1, also known as MAP4K1) is a mammalian Ste20-like serine / threonine kinase. As the expression product of the gene MAP4K1, it is primarily expressed in hematopoietic stem cells and belongs to the mitogen-activated protein kinase kinase kinase kinase kinase (MAP4K) family. This family currently includes five other members: MAP4K2, MAP4K3, MAP4K4, MAP4K5, and MAP4K6. HPK1 is a 97 kDa protein composed of three main regions: an N-terminal Ste20-like kinase domain, a C-terminal kinase domain, and four proline-rich regions (P1, P2, P3, and P4) in the middle segment. This middle region typically interacts with adaptor proteins containing SH2 / SH3 domains to activate the transduction of a series of signaling pathways.

[0003] When HPK1 is activated by various upstream signaling factors, including epidermal growth factor, prostaglandin E2, tumor growth factor, erythropoietin, T cell receptors, and B cell receptors, it triggers a series of biological cascade reactions. HPK1 can also interact with downstream adaptor proteins in the SLP-76 family, CARD11, GRB2 family, and CRK family, activating the JNK / SAPK signaling pathway in hematopoietic stem cells, thereby negatively regulating the T cell pathway. Therefore, HPK1 participates in the regulation of cell proliferation and apoptosis and plays an important role in immunosuppression.

[0004] HPK1, as a kinase that regulates immunosuppression, is a reverse regulator of the T cell receptor. When the T cell receptor is activated, HPK1 in the cytoplasm is recruited and aggregated near the cell membrane. The activated HPK1 phosphorylates the adaptor protein SLP76. The activated SLP76 serves as a docking site for the T cell regulatory inhibitory protein 14-3-3. Multiple proteins combine to form the SLP76 complex, which triggers ubiquitination degradation, ultimately leading to the instability of the T cell receptor signaling complex, thereby downregulating the T cell signaling pathway and T cell proliferation.

[0005] However, T cells participate in crucial anti-tumor immunity processes, directly killing tumor cells through their antigen receptors, which recognize specific antibodies on tumor cells; or indirectly killing tumor cells through activation of macrophages and secretion of other lymphokines. Therefore, inhibition of HPK1 can promote T cell proliferation and activate T cell signaling pathways, further enhancing tumor killing and inhibiting tumor growth. Due to its important role in immune regulation, HPK1 has potential research implications for the treatment of inflammatory responses, autoimmune diseases (such as systemic lupus erythematosus and psoriasis), and malignancies (such as acute myeloid leukemia, urothelial carcinoma, colon cancer, and pancreatic cancer).

[0006] Even though only two HPK1 inhibitors have entered clinical trials—Treadwell's CFI-402411 (Phase II) and BeiGene's BGB-15025 (Phase I)—in the fierce battle against cancer, pharmaceutical researchers are unwilling to lag behind, and a growing number of pharmaceutical companies, such as Nimbus Therapeutics and Arno Pharmaceuticals, have joined the fray. HPK1 inhibitors are a cutting-edge research area, and their treatment inevitably triggers a T-cell-related immune response. Therefore, finding safer and more effective HPK1 inhibitors is crucial to reduce treatment risks and alleviate patient suffering.

[0007] Summary of the Invention

[0008] In order to solve the above technical problems, the present invention provides a compound represented by general formula (I) or its stereoisomers, tautomers or pharmaceutically acceptable salts:

[0009] in:

[0010] Ring A selects the following groups:

[0011] X is selected from CR a or N;

[0012] R a 、R b are the same or different and are each independently selected from a hydrogen atom, a halogen, a hydroxyl, an amino, an alkyl, an alkoxy or a cyano group; wherein the alkyl or alkoxy group is optionally further substituted by one or more substituents selected from a halogen, a hydroxyl, a cyano group, an alkyl or an alkoxy group;

[0013] R 3 The same or different, each independently selected from hydrogen atom, hydroxyl, halogen, alkyl, cyano, alkoxy, cycloalkyl, heterocyclic group or -NR c R dwherein the alkyl, alkoxy, cycloalkyl or heterocyclic group is optionally further substituted with one or more halogen, amino, hydroxy, cyano, alkyl or alkoxy substituents;

[0014] R c 、R d The same or different, each independently selected from hydrogen atom, alkyl, cycloalkyl, heterocyclic group, -C(O)R 4 or -S(O)2R 4 ; wherein the alkyl, cycloalkyl or heterocyclic group is optionally further substituted by one or more substituents selected from halogen, amino, hydroxy, cyano, alkyl or alkoxy;

[0015] L is selected from a bond, -C(O)-, -OC(O)-, -SC(O)-, -CH2C(O)- or -NR e C(O)-;

[0016] R e is selected from a hydrogen atom or an alkyl group;

[0017] Ring B is selected from a fused ring, an aryl group, a heteroaryl group, a cycloalkyl group or a heterocyclyl group;

[0018] R 1 are the same or different and are each independently selected from alkyl, cycloalkyl, aryl, heteroaryl, heterocyclic or fused ring, wherein the alkyl, cycloalkyl, aryl, heteroaryl, heterocyclic or fused ring is optionally further substituted by one or more R A replaced by;

[0019] Each R A The same or different, each independently selected from alkyl, halogen, nitro, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -OR 4 、-C(O)R 4 、-C(O)OR 4 、-NHC(O)R 4 、-NHC(O)OR 4 、-NR 5 R 6 、-C(O)NR 5 R 6 、-CH2NHC(O)OR 4 、-CH2NR 5 R 6 、-P(O)R 5 R 6 、-S(O) r NR 5 R 6 or -S(O) r R 4wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl or heteroaryl is optionally further substituted by one or more groups selected from alkyl, halogen, nitro, cyano, cycloalkyl, heterocyclic, aryl, heteroaryl, =O, -OR 4 、-C(O)R 4 、-C(O)OR 4 、-NHC(O)R 4 、-NHC(O)OR 4 、-NR 5 R 6 、-C(O)NR 5 R 6 、-CH2NHC(O)OR 4 、-CH2NR 5 R 6 or -S(O) r R 4 substituted by a substituent;

[0020] Or, two R A Together with the carbon atom to which it is attached, it forms a -C(=O)-;

[0021] R 2 The same or different, each independently selected from hydrogen atom, alkyl, halogen, nitro, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl, heteroaryl, -OR 4 、-C(O)R 4 、-C(O)OR 4 、-NHC(O)R 4 、-NHC(O)OR 4 、-NR 5 R 6 、-C(O)NR 5 R 6 、-CH2NHC(O)OR 4 、-CH2NR 5 R 6 or -S(O) r R 4 wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally further substituted by one or more R B replaced by;

[0022] Or, two R 2 Together with the carbon atom to which it is attached, it forms a -C(=O)-;

[0023] Each R B The same or different, each independently selected from alkyl, halogen, nitro, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -OR 4 、-C(O)R4 、-C(O)OR 4 、-NHC(O)R 4 、-NHC(O)OR 4 、-NR 5 R 6 、-C(O)NR 5 R 6 、-CH2NHC(O)OR 4 、-CH2NR 5 R 6 or -S(O) r R 4 wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl or heteroaryl is optionally further substituted by one or more groups selected from alkyl, halogen, nitro, cyano, cycloalkyl, heterocyclic, aryl, heteroaryl, =O, -OR 4 、-C(O)R 4 、-C(O)OR 4 、-NHC(O)R 4 、-NHC(O)OR 4 、-NR 5 R 6 、-C(O)NR 5 R 6 、-CH2NHC(O)OR 4 、-CH2NR 5 R 6 or -S(O) r R 4 substituted by a substituent;

[0024] Or, two R B Together with the carbon atom to which it is attached, it forms a -C(=O)-;

[0025] R 4 Each is independently selected from a hydrogen atom, an alkyl group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein the alkyl group, the cycloalkyl group, the heterocyclic group, the aryl group or the heteroaryl group is optionally further substituted by one or more hydroxyl groups, halogen groups, nitro groups, cyano groups, alkyl groups, alkoxy groups, haloalkyl groups, haloalkoxy groups, cycloalkyl groups, heterocyclic groups, aryl groups, heteroaryl groups, =O, -C(O)R 7 、-C(O)OR 7 、-OC(O)R 7 、-NR 8 R 9 、-C(O)NR 8 R 9 、-SO2NR 8 R 9 or -NR 8 C(O)R 9 substituted by a substituent;

[0026] R 5 and R 6 Each is independently selected from hydrogen, hydroxy, halogen, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally further substituted by one or more selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, =O, -C(O)R 7 、-C(O)OR 7 、-OC(O)R 7 、-NR 8 R 9 、-C(O)NR 8 R 9 、-SO2NR 8 R 9 or -NR 8 C(O)R 9 substituted by a substituent;

[0027] Or, R 5 and R 6 Together with the atoms to which they are attached, they form a 4- to 8-membered heterocyclic group, wherein the 4- to 8-membered heterocyclic group contains one or more N, O or S(O) r , and the 4- to 8-membered heterocyclic group is optionally further substituted by one or more selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, =O, -C(O)R 7 、-C(O)OR 7 、-OC(O)R 7 、-NR 8 R 9 、-C(O)NR 8 R 9 、-SO2NR 8 R 9 or -NR 8 C(O)R 9 substituted by a substituent;

[0028] R 7 、R 8 and R 9 Each is independently selected from a hydrogen atom, an alkyl group, an amino group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein the alkyl group, the cycloalkyl group, the heterocyclic group, the aryl group or the heteroaryl group is optionally further substituted with one or more substituents selected from a hydroxyl group, a halogen group, a nitro group, an amino group, a cyano group, an alkyl group, an alkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group, a heteroaryl group, a carboxyl group or a carboxylate group;

[0029] m is selected from 0, 1, 2, 3, 4 or 5; and

[0030] r is 0, 1, or 2.

[0031] A preferred embodiment of the present invention is a compound of formula (I) or its stereoisomers, tautomers or pharmaceutically acceptable salts, which is a compound of formula (II), (III), (IV) or (V) or its stereoisomers, tautomers or pharmaceutically acceptable salts:

[0032] Among them: Ring B, L, R 1 ~R 3 、R a 、R b and m are as defined in the general formula (I).

[0033] A preferred embodiment of the present invention is a compound of formula (I), (II), (III), (IV) or (V) or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof, wherein R1 is selected from aryl, heteroaryl, heterocyclic group or fused ring, wherein the aryl, heteroaryl, heterocyclic group or fused ring is optionally further substituted by one or more groups selected from alkyl, halogen, hydroxyl, amino, hydroxyalkyl, =O, -P(O)R 5 R 6 、-S(O) r NR 5 R 6 or -S(O) r R 4 substituted by a substituent;

[0034] The R 4 、R 5 、R 6 are each independently selected from a hydrogen atom or an alkyl group; r is 0, 1 or 2.

[0035] A preferred embodiment of the present invention is a compound of formula (I), (II), (III), (IV) or (V) or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof, wherein R 1 Selected from the following groups:

[0036] A preferred embodiment of the present invention is a compound of formula (I), (II), (III), (IV) or (V) or its stereoisomers, tautomers or pharmaceutically acceptable salts, wherein L is selected as a bond.

[0037] A preferred embodiment of the present invention is a compound of formula (I), (II), (III), (IV) or (V) or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof, wherein L is selected from -C(O)-, -OC(O)- or -NR eC(O)-; wherein the R e is selected from a hydrogen atom or a methyl group.

[0038] A preferred embodiment of the present invention is a compound of formula (I), (II), (III), (IV) or (V) or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof, wherein ring B is selected from the following groups:

[0039] A preferred embodiment of the present invention is a compound of formula (I), (II), (III), (IV) or (V) or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof, wherein R 2 the same or different, each independently selected from a hydrogen atom, an alkyl group, a halogen group, a cyano group, an alkoxy group, a cycloalkyl group, a heterocyclic group or -C(O)NR 5 R 6 wherein the alkyl, alkoxy, cycloalkyl or heterocyclic group is optionally further substituted by one or more R B replaced by;

[0040] Or, two R 2 Together with the carbon atom to which it is attached, it forms a -C(=O)-;

[0041] R B The same or different, each independently selected from alkyl, halogen, hydroxy, cyano, alkoxy, cycloalkyl, heterocyclyl or -C(O)NR 5 R 6 wherein the alkyl, alkoxy, cycloalkyl or heterocyclic group is optionally further substituted by one or more substituents selected from alkyl, halogen, cyano, hydroxy, amino, alkoxy, haloalkyl, hydroxyalkyl or haloalkoxy;

[0042] The R 5 、R 6 are each independently selected from a hydrogen atom or an alkyl group.

[0043] A preferred embodiment of the present invention is a compound of formula (I), (II), (III), (IV) or (V) or its stereoisomers, tautomers or pharmaceutically acceptable salts, wherein Selected from the following groups:

[0044] A preferred embodiment of the present invention is a compound of formula (I), (II), (III), (IV) or (V) or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof, wherein R 3 is selected from amino or halogen.

[0045] In a preferred embodiment of the present invention, the compound described by general formula (I) is selected from:

[0046] or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof.

[0047] Note: If there is a discrepancy between a drawn structure and the name given for that structure, the drawn structure will be given greater weight.

[0048] Furthermore, the present invention provides a pharmaceutical composition comprising an effective dose of a compound of formula (I), (II), (III), (IV) or (V) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, excipient or a combination thereof.

[0049] The present invention provides a use of a compound of general formula (I), (II), (III), (IV) or (V) or its stereoisomers, tautomers or pharmaceutically acceptable salts, or a pharmaceutical composition thereof in the preparation of an HPK1 inhibitor.

[0050] The present invention also provides a use of a compound of formula (I), (II), (III), (IV) or (V) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, in the preparation of a medicament for treating a disease mediated by HPK1, wherein the disease mediated by HPK1 is preferably inflammation, an autoimmune disease or a tumor, wherein the autoimmune disease is preferably systemic lupus erythematosus or psoriasis; wherein the tumor is preferably a malignant blood tumor or a malignant solid tumor; wherein the tumor is more preferably selected from acute myeloid leukemia, bladder cancer, colon cancer, rectal cancer, pancreatic cancer, lung cancer, small cell lung cancer, non-small cell lung cancer, lymphoma, blastoma, retinoblastoma, sarcoma, prostate cancer, bile duct cancer, esophageal cancer, gastric cancer, liver cancer, glioma, cervical cancer, ovarian cancer, head and neck cancer or multiple myeloma.

[0051] The present invention further provides a use of a compound of formula (I), (II), (III), (IV) or (V) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, in the preparation of a medicament for treating inflammation, autoimmune diseases or tumor diseases, wherein the autoimmune disease is preferably systemic lupus erythematosus or psoriasis; wherein the tumor is preferably a malignant blood tumor or a malignant solid tumor; wherein the tumor is more preferably acute myeloid leukemia, bladder cancer, colon cancer, rectal cancer, pancreatic cancer, lung cancer, small cell lung cancer, non-small cell lung cancer, lymphoma, blastoma, retinoblastoma, sarcoma, prostate cancer, bile duct cancer, esophageal cancer, gastric cancer, liver cancer, glioma, cervical cancer, ovarian cancer, head and neck cancer or multiple myeloma.

[0052] Detailed Description of the Invention

[0053] Unless otherwise stated, some of the terms used in the specification and claims of the present invention are defined as follows:

[0054] "Alkyl" when used as a group or a part of a group refers to a group comprising C1-C 20 A straight chain or branched aliphatic hydrocarbon group. Preferably C1-C 10 Alkyl, more preferably C1-C6 alkyl. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, etc. Alkyl can be substituted or unsubstituted.

[0055] "Cycloalkyl" refers to a saturated or partially saturated monocyclic, fused, bridged, or spirocyclic carbon ring. 12 Cycloalkyl, more preferably C3-C8 cycloalkyl, most preferably C3-C6 cycloalkyl. Examples of monocyclic cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, etc., preferably cyclopropyl and cyclohexenyl. Cycloalkyl may be substituted or unsubstituted.

[0056] "Spiroalkyl" refers to a polycyclic group with 5 to 18 members, two or more cyclic structures, and one carbon atom (called spiro atom) shared between the monocyclic rings, containing one or more double bonds in the ring, but no ring has a completely conjugated π electron aromatic system. Preferably, it is 6 to 14 members, more preferably 7 to 10 members. According to the number of spiro atoms shared between the rings, the spiroalkyl group is divided into single spiro, double spiro or multiple spiroalkyl groups, preferably single spiro and double spiroalkyl groups, preferably 4 / 5 members, 4 / 6 members, 5 / 5 members or 5 / 6 members. Non-limiting examples of "spiroalkyl" include, but are not limited to, spiro[4.5]decyl, spiro[4.4]nonyl, spiro[3.5]nonyl, spiro[2.4]heptyl.

[0057] "Fused cycloalkyl" refers to a 5- to 18-membered, all-carbon polycyclic group containing two or more cyclic structures sharing a pair of carbon atoms. One or more rings may contain one or more double bonds, but no ring has a completely conjugated π electron aromatic system. It is preferably 6- to 12-membered, and more preferably 7- to 10-membered. Depending on the number of constituent rings, it can be classified as a bicyclic, tricyclic, tetracyclic, or polycyclic fused cycloalkyl group, preferably a bicyclic or tricyclic group, and more preferably a 5-membered / 5-membered or 5-membered / 6-membered bicyclic alkyl group. Non-limiting examples of "fused cycloalkyl" include, but are not limited to, bicyclo[3.1.0]hexyl, bicyclo[3.2.0]hept-1-enyl, bicyclo[3.2.0]heptyl, decahydronaphthyl, or tetradecahydrophenanthrenyl.

[0058] "Bridged cycloalkyl" refers to an all-carbon polycyclic group with 5 to 18 members, containing two or more cyclic structures that share two non-directly connected carbon atoms. One or more rings may contain one or more double bonds, but none of the rings have completely conjugated π electrons. It is an aromatic system with preferably 6 to 12 members, more preferably 7 to 10 members. It is preferably 6 to 14 members, more preferably 7 to 10 members. Depending on the number of constituent rings, bridged cycloalkyl groups can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic, preferably bicyclic, tricyclic, or tetracyclic, and more preferably bicyclic or tricyclic. Non-limiting examples of "bridged cycloalkyl" include, but are not limited to: (1s,4s)-bicyclo[2.2.1]heptyl, bicyclo[3.2.1]octyl, (1s,5s)-bicyclo[3.3.1]nonyl, bicyclo[2.2.2]octyl, and (1r,5r)-bicyclo[3.3.2]decyl.

[0059] "Heterocyclyl," "heterocycloalkyl," "heterocycle," or "heterocyclic" are used interchangeably herein to refer to a non-aromatic heterocyclic group in which one or more ring atoms are selected from nitrogen, oxygen, or S(O) r(wherein r is selected from 0,1 or 2) heteroatoms, including monocycle, polycycle, condensed ring, bridged ring and spirocycle.Preferably there are 5 to 7 yuan monocycle or 7 to 10 yuan bicyclic or tricyclic ring, which can include 1,2 or 3 atoms selected from nitrogen, oxygen and / or sulfur.The example of " heterocyclic radical " includes but is not limited to morpholinyl, oxetanyl, azetidinyl, thiomorpholinyl, tetrahydrofuranyl, tetrahydropyranyl, 1,1-dioxo-thiomorpholinyl, piperidinyl, 2-oxo-piperidinyl, pyrrolidinyl, 2-oxo-pyrrolidinyl, piperazine-2-one, 8-oxa-3-aza-bicyclo [3.2.1] octyl, piperazinyl, hexahydropyrimidine, The heterocyclic group may be substituted or unsubstituted.

[0060] "Spiro heterocyclyl" refers to a polycyclic group with 5 to 18 members, two or more ring structures, and one atom shared between the rings, containing one or more double bonds in the ring, but no ring has a completely conjugated π electron aromatic system, wherein one or more ring atoms are selected from nitrogen, oxygen or S(O) r (wherein r is selected from 0, 1 or 2) heteroatoms, and the remaining ring atoms are carbon. Preferably 6 to 14 members, more preferably 7 to 10 members. According to the number of shared spiro atoms between rings, spirocycloalkyl is divided into single spiro heterocyclic group, double spiro heterocyclic group or multiple spiro heterocyclic group, preferably single spiro heterocyclic group and double spiro heterocyclic group. More preferably, it is 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 5-membered or 5-membered / 6-membered single spiro heterocyclic group. Non-limiting examples of "spiro heterocyclic group" include but are not limited to: 1,7-dioxaspiro[4.5]decyl, 2-oxa-7-azaspiro[4.4]nonyl, 7-oxaspiro[3.5]nonyl, 5-oxaspiro[2.4]heptyl.

[0061] "Fused heterocyclic group" refers to an all-carbon polycyclic group containing two or more ring structures sharing a pair of atoms, one or more rings may contain one or more double bonds, but no ring has a completely conjugated π-electron aromatic system, wherein one or more ring atoms are selected from nitrogen, oxygen or S(O) r (wherein r is selected from 0, 1 or 2) heteroatom, and the remaining ring atoms are carbon. Preferably it is 6 to 14 members, more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclic groups, preferably bicyclic or tricyclic, more preferably 5-membered / 5-membered or 5-membered / 6-membered bicyclic fused heterocyclic groups. Non-limiting examples of "fused heterocyclic groups" include, but are not limited to: octahydropyrrolo[3,4-c]pyrrolyl, octahydro-1H-isoindolyl, 3-azabicyclo[3.1.0]hexyl, octahydrobenzo[b][1,4]dioxin.

[0062] "Bridged heterocyclic group" refers to a 5- to 14-membered, 5- to 18-membered polycyclic group containing two or more ring structures that share two atoms that are not directly connected to each other, one or more rings may contain one or more double bonds, but no ring has a completely conjugated π-electron aromatic system, wherein one or more ring atoms are selected from nitrogen, oxygen or S(O) r (wherein r is selected from 0, 1 or 2) heteroatoms, and the remaining ring atoms are carbon. Preferably 6 to 14 members, more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged heterocyclic groups, preferably bicyclic, tricyclic or tetracyclic, more preferably bicyclic or tricyclic. Non-limiting examples of "bridged heterocyclic groups" include but are not limited to: 2-azabicyclo [2.2.1] heptyl, 2-azabicyclo [2.2.2] octyl, 2-azabicyclo [3.3.2] decyl.

[0063] "Aryl" refers to a carbocyclic aromatic system containing one or two rings, wherein the rings may be joined together in a fused manner. The term "aryl" includes monocyclic or bicyclic aromatic groups, such as phenyl, naphthyl, tetrahydronaphthyl aromatic groups. Preferably, aryl is C6-C 10 The aryl group is more preferably phenyl and naphthyl, and most preferably naphthyl. The aryl group may be substituted or unsubstituted.

[0064] "Heteroaryl" refers to an aromatic 5-6 membered monocyclic or 8-10 membered bicyclic ring which may contain 1 to 4 atoms selected from nitrogen, oxygen and / or sulfur. Examples of "heteroaryl" include, but are not limited to, furyl, pyridyl, 2-oxo-1,2-dihydropyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, thienyl, isoxazolyl, oxazolyl, oxadiazolyl, imidazolyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, benzodioxolyl, benzothienyl, benzimidazolyl, indolyl, isoindolyl, 1,3-dioxo-isoindolyl, quinolyl, indazolyl, benzisothiazolyl, benzoxazolyl, benzisoxazolyl. Heteroaryl may be substituted or unsubstituted.

[0065] "Fused ring" refers to a polycyclic group in which two or more cyclic structures share a pair of atoms, one or more rings may contain one or more double bonds, but at least one ring does not have a completely conjugated π-electron aromatic system, and at least one ring has a completely conjugated π-electron aromatic system, wherein the ring atoms are selected from 0, one or more selected from nitrogen, oxygen or S(O) r(wherein r is selected from 0, 1 or 2) heteroatoms, and the remaining ring atoms are carbon. The fused ring is preferably a bicyclic or tricyclic fused ring, wherein the bicyclic fused ring is preferably a fused ring of a monocyclic aryl or a monocyclic heteroaryl and a monocyclic heterocyclic radical or a monocyclic cycloalkyl, and the tricyclic fused ring is preferably a fused ring of a monocyclic aryl or a monocyclic heteroaryl and a bicyclic heterocyclic radical or a bicyclic cycloalkyl. The fused ring is preferably a 7 to 14-membered ring. Examples of "fused ring" include but are not limited to:

[0066] "Alkoxy" refers to a group (alkyl-O-). Alkyl is defined herein. C1-C6 alkoxy groups are preferred. Examples include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, and tert-butoxy.

[0067] "Hydroxy" refers to an -OH group.

[0068] "Halogen" refers to fluorine, chlorine, bromine and iodine.

[0069] "Amino" refers to -NH2.

[0070] "Cyano" refers to -CN.

[0071] "Nitro" refers to -NO2.

[0072] "Benzyl" refers to -CH2-phenyl.

[0073] "Carboxyl" refers to -C(O)OH.

[0074] "Carboxylate" refers to a -C(O)O-alkyl group or a -C(O)O-cycloalkyl group, wherein alkyl and cycloalkyl are as defined above.

[0075] "DMSO" refers to dimethyl sulfoxide.

[0076] "BOC" refers to tert-butoxycarbonyl.

[0077] "TFA" refers to trifluoroacetic acid.

[0078] "Ts" refers to p-toluenesulfonyl.

[0079] "Tf" refers to p-trifluoromethylbenzenesulfonyl.

[0080] "Hydroxyalkyl" refers to an alkyl group substituted with a hydroxy group.

[0081] "Haloalkyl" refers to an alkyl group substituted with a halogen.

[0082] "Haloalkoxy" refers to an alkoxy group substituted with a halogen.

[0083] "Leaving group", or leaving group, is an atom or functional group that breaks away from a larger molecule in a chemical reaction. It is a term used in nucleophilic substitution reactions and elimination reactions. In a nucleophilic substitution reaction, the reactant attacked by the nucleophile is called the substrate, and the atom or group of atoms that breaks away from the substrate molecule with a pair of electrons is called the leaving group. Groups that easily accept electrons and have a strong ability to withstand negative charges are good leaving groups. The smaller the pKa of the conjugate acid of the leaving group, the easier it is for the leaving group to break away from other molecules. The reason is that when the pKa of its conjugate acid is smaller, the corresponding leaving group does not need to bind to other atoms, and the tendency to exist as an anion (or an electrically neutral leaving group) is enhanced. Common leaving groups include but are not limited to halogens, methylsulfonyl, -OTs, -OTf or -OH.

[0084] "Substituted" means that one or more hydrogen atoms, preferably up to 5, more preferably 1 to 3 hydrogen atoms, in a group are replaced independently of one another by a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and a person skilled in the art can determine (by experiment or theory) which substitutions are possible or impossible without undue effort. For example, an amino or hydroxyl group with free hydrogen may be unstable when combined with a carbon atom with an unsaturated (e.g., olefinic) bond.

[0085] The term "substituted" or "substituted" as used herein, unless otherwise specified, means that a group may be substituted by one or more groups selected from the group consisting of alkyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, amino, haloalkyl, hydroxyalkyl, carboxyl, and carboxylate;

[0086] "Pharmaceutically acceptable salts" refer to salts of the above compounds that retain their original biological activity and are suitable for pharmaceutical use. Pharmaceutically acceptable salts of the compounds represented by general formula (I) may be metal salts or amine salts formed with suitable acids.

[0087] A "pharmaceutical composition" refers to a mixture containing one or more compounds described herein, or their physiologically acceptable salts or prodrugs, together with other chemical components, as well as other components such as physiologically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitating absorption of the active ingredients and thereby exerting their biological activity.

[0088] Synthesis method of the compound of the present invention

[0089] In order to achieve the purpose of the present invention, the present invention adopts the following technical solutions:

[0090] The present invention provides a method for preparing a compound of general formula (I) or its stereoisomers, tautomers or pharmaceutically acceptable salts, the method comprising:

[0091] When L is a bond:

[0092] The compound of formula (IA) and the compound of formula (IB) undergo a coupling reaction under metal catalysis to obtain a compound of formula (I);

[0093] in:

[0094] Y is selected from a leaving group, wherein the leaving group is selected from halogen or OTf;

[0095] Ring A, Ring B, R 2 and m are as described in general formula (I). DETAILED DESCRIPTION

[0096] The present invention is further described below with reference to the following examples, but these examples are not intended to limit the scope of the present invention.

[0097] Example

[0098] The examples provide the preparation of representative compounds represented by formula (I) and related structural identification data. It must be noted that the following examples are used to illustrate the present invention rather than to limit the present invention. 1 H NMR spectra were obtained using a Bruker instrument (400 MHz), and chemical shifts are expressed in ppm using tetramethylsilane as an internal standard (0.00 ppm). 1 H NMR notation: s = singlet, d = doublet, t = triplet, m = multiplet, br = broadened, dd = doublet of a doublet, dt = doublet of a triplet. Coupling constants, when given, are given in Hz.

[0099] Mass spectra were obtained using LC / MS, and the ionization method could be ESI or APCI.

[0100] The thin layer chromatography silica gel plate uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate. The specification of the silica gel plate used in thin layer chromatography (TLC) is 0.15mm~0.2mm, and the specification used for thin layer chromatography separation and purification products is 0.4mm~0.5mm.

[0101] Column chromatography generally uses Yantai Huanghai silica gel 200-300 mesh silica gel as the carrier.

[0102] In the following examples, unless otherwise indicated, all temperatures are in degrees Celsius. Unless otherwise indicated, various starting materials and reagents are commercially available or synthesized according to known methods. Commercially available raw materials and reagents are used directly without further purification, unless otherwise indicated. Commercial manufacturers include but are not limited to Aldrich Chemical Company, ABCR GmbH & Co. KG, Acros Organics, Guangzan Chemical Technology Co., Ltd. and Jingyan Chemical Technology Co., Ltd.

[0103] CD3OD: deuterated methanol.

[0104] CDCl3: deuterated chloroform.

[0105] DMSO-d6: deuterated dimethyl sulfoxide.

[0106] Argon atmosphere means that the reaction bottle is connected to an argon balloon with a capacity of about 1 L.

[0107] Unless otherwise specified in the examples, the solution in the reaction refers to an aqueous solution.

[0108] The compound is purified using a silica gel column chromatography eluent system and thin layer chromatography, wherein the eluent system is selected from: A: petroleum ether and ethyl acetate system; B: dichloromethane and methanol system; C: dichloromethane:ethyl acetate; the volume ratio of the solvent varies according to the polarity of the compound and can also be adjusted by adding a small amount of acidic or alkaline reagents, such as acetic acid or triethylamine.

[0109] Example 1

[0110] N 2 -(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-8-phenylquinazoline-2,5-diamine

[0111] first step

[0112] 8-Bromo-5-chloroquinazolin-2-amine

[0113] Guanidine 1b (2.05 g, 11.37 mmol) was added to N,N-dimethylacetamide (60 mL). Potassium carbonate (4.71 g, 34.11 mmol) was added with stirring at room temperature, followed by the dropwise addition of a solution of 3-bromo-6-chloro-2-fluorobenzaldehyde 1a (2.7 g, 11.37 mmol) in N,N-dimethylacetamide (10 mL). The mixture was heated to 160°C under nitrogen for 8 hours. After cooling, 50 mL of water was added to the reaction solution, which was then extracted with ethyl acetate (100 mL x 3). The organic phases were combined and washed with water (200 mL x 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by column chromatography (eluent: System B) to afford 8-bromo-5-chloroquinazolin-2-amine 1c (2.5 g) in an 85% yield.

[0114] MS m / z(ESI):258.0[M+1].

[0115] Step 2

[0116] 5-Chloro-8-phenylquinazolin-2-amine

[0117] 8-Bromo-5-chloroquinazolin-2-amine 1c (1.91 g, 7.38 mmol) and phenylboronic acid 1d (1.8 g, 14.76 mmol) were dissolved in a mixture of 1,4-dioxane and water (V:V = 50 mL:5 mL). [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (0.54 g, 0.74 mmol) and potassium carbonate (3.06 g, 22.14 mmol) were added sequentially. The mixture was heated to 60°C for 8 hours. The mixture was cooled, filtered, and the filter cake was rinsed with ethyl acetate. The organic phase was concentrated under reduced pressure, and the resulting residue was purified by column chromatography (eluent: System B) to afford 5-chloro-8-phenylquinazolin-2-amine 1e (1.4 g) in a 74% yield.

[0118] MS m / z(ESI):256.1[M+1].

[0119] Step 3

[0120] 5-Chloro-N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-8-phenylquinazolin-2-amine

[0121] 5-Chloro-8-phenylquinazolin-2-amine 1e (0.9 g, 3.54 mmol) and 7-bromo-2-methyl-1,2,3,4-tetrahydroisoquinoline 1f (0.8 g, 3.54 mmol) were dissolved in 1,4-dioxane (50 mL), and tris(dibenzylideneacetone)dipalladium (0.65 g, 0.71 mmol), 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene (0.41 g, 0.71 mmol) and cesium carbonate (3.46 g, 10.61 mmol) were added in sequence, and the mixture was heated to 90 °C for 7 hours. The mixture was cooled, filtered, and the filter cake was washed. The organic phase was concentrated under reduced pressure. The residue was separated and purified by column chromatography (eluent: System B) to give 1 g (1.15 g) of 5-chloro-N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-8-phenylquinazolin-2-amine in an 81% yield.

[0122] MS m / z(ESI):401.2[M+1].

[0123] Step 4

[0124] tert-Butyl (2-((2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)-8-phenylquinazolin-5-yl)carbamate

[0125] 1 g (0.8 g, 2.0 mmol) of 5-chloro-N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-8-phenylquinazolin-2-amine was dissolved in 1,4-dioxane (40 mL), and tert-butyl carbamate (3.51 g, 29.9 mmol), tris(dibenzylideneacetone)dipalladium-chloroform adduct (0.41 g, 0.40 mmol), 2-(dicyclohexylphosphine)3,6-dimethoxy-2',4',6'-triisopropyl-1,1'-biphenyl (0.21 g, 0.40 mmol), cesium carbonate (1.95 g, 5.99 mmol) and The mixture was reacted at 90°C for 6 hours. The mixture was cooled, filtered, and the filter cake was washed. The organic phase was concentrated under reduced pressure, and the resulting residue was separated and purified by column chromatography (eluent: System B) to obtain tert-butyl (2-((2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)-8-phenylquinazolin-5-yl)carbamate 1h (0.6 g) in a 62% yield.

[0126] MS m / z(ESI):482.3[M+1].

[0127] Step 5

[0128] N 2 -(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-8-phenylquinazoline-2,5-diamine

[0129] Tert-butyl (2-((2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)-8-phenylquinazolin-5-yl)carbamate 1h (0.55 g, 1.14 mmol) was dissolved in dichloromethane (20 mL), trifluoroacetic acid (0.65 g, 5.71 mmol) was added to the solution, and the solution was stirred at room temperature for 18 hours. The reaction was diluted with water, and after separating the aqueous phase, 20% sodium hydroxide was added to alkalize to pH = 10. The mixture was extracted with dichloromethane / methanol (ratio 10 / 1), dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting residue was purified by column chromatography (eluent: System A) to obtain N 2 -(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-8-phenylquinazoline-2,5-diamine 1 (0.11 g), yield: 25%.

[0130] MS m / z(ESI):382.2[M+1].

[0131] 1 HNMR(400MHz,DMSO-d6)δ9.53(s,1H),9.46(s,1H),7.72(s,1H),7.59-7.62(m,2H),7.42-7.48(m,4H),7.30-7.35(m,1H),6.8 8(d,J=8.4Hz,1H),6.53(d,J=8.0Hz,1H),6.38(s,2H),3.27-3.29(m,2H),2.72-2.74(m,2H),2.58-2.62(m,2H),2.37(s,3H).

[0132] Example 2

[0133] N 2 -(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-8-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazoline-2,5-diamine

[0134] first step

[0135] tert-Butyl 7-(2-amino-5-chloroquinazolin-8-yl)-8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate

[0136] 8-Bromo-5-chloroquinazolin-2-amine 1c (1.0 g, 3.87 mmol) and 8-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylic acid tert-butyl ester 2a (1.75 g, 4.64 mmol, prepared according to patent CN114853730) were dissolved in a mixed solution of 1,4-dioxane and water (22 mL, V:V = 10:1). [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (0.28 g, 0.38 mmol) and potassium carbonate (1.60 g, 11.61 mmol) were added sequentially, and the mixture was heated to 60°C for 6.5 hours. The reaction mixture was cooled and filtered, and the filter cake was rinsed with a mixed solvent of dichloromethane and methanol (30 mL, V:V = 10:1 mL). The organic phase was concentrated under reduced pressure, and the resulting residue was separated and purified by column chromatography (eluent: System A) to give tert-butyl 7-(2-amino-5-chloroquinazolin-8-yl)-8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate 2b (1.14 g) in a yield of 68%.

[0137] MS m / z(ESI):428.1[M+1].

[0138] Step 2

[0139] tert-Butyl 7-(5-chloro-2-((2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)quinazolin-8-yl)-8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate

[0140] Tert-butyl 7-(2-amino-5-chloroquinazolin-8-yl)-8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate 2b (1.14 g, 2.65 mmol) and 7-bromo-2-methyl-1,2,3,4-tetrahydroisoquinoline 1f (0.6 g, 2.65 mmol) were dissolved in 1,4-dioxane (50 mL), and tris(dibenzylideneacetone)dipalladium (0.48 g, 0.53 mmol), 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene (0.31 g, 0.53 mmol) and cesium carbonate (2.59 g, 7.96 mmol) were added in sequence, and the mixture was heated to 90 °C for 6 hours. The mixture was cooled, filtered, and the filter cake was washed. The organic phase was concentrated under reduced pressure, and the residue was separated and purified by column chromatography (eluent: System A) to give tert-butyl 7-(5-chloro-2-((2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)quinazolin-8-yl)-8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate 2c (0.95 g) in a yield of 62%.

[0141] MS m / z(ESI):573.2[M+1].

[0142] Step 3

[0143] tert-Butyl 7-(5-((tert-Butoxycarbonyl)amino)-2-((2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)quinazolin-8-yl)-8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate

[0144] 7-(5-chloro-2-((2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)quinazolin-8-yl)-8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylic acid tert-butyl ester 2c (0.9 g, 1.57 mmol) was dissolved in 1,4-dioxane (80 mL), and tert-butyl carbamate (2.76 g, 23.56 mmol), tris(dibenzylideneacetone)dipalladium (0.21 g, 0.31 mmol), 2-(dicyclohexylphosphine)3,6-dimethoxy-2',4',6'-triisopropyl-1,1'-biphenyl (0.17 g, 0.31 mmol), cesium carbonate (1.54 g, 4.71 mmol) and The mixture was reacted at 90°C for 5 hours with the addition of 1% zeolite (0.70 g). The mixture was cooled, filtered, and the filter cake was washed. The organic phase was concentrated under reduced pressure, and the resulting residue was separated and purified by column chromatography (eluent: System B) to give tert-butyl 7-(5-((tert-butoxycarbonyl)amino)-2-((2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)quinazolin-8-yl)-8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate 2d (0.65 g) in a 63% yield.

[0145] MS m / z(ESI):654.4[M+1].

[0146] Step 4

[0147] N 2 -(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-8-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazoline-2,5-diamine

[0148] 7-(5-((tert-Butoxycarbonyl)amino)-2-((2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)quinazolin-8-yl)-8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylic acid tert-butyl ester 2d (0.6 g, 0.92 mmol) was dissolved in dichloromethane (20 mL), trifluoroacetic acid (0.20 g, 1.84 mmol) was added to the solution, and the solution was stirred at room temperature for 16 hours. The reaction was diluted with water, and after separating the aqueous phase, 20% aqueous sodium hydroxide solution was added to alkalize to pH = 10. The mixture was extracted with a mixed solvent of dichloromethane and methanol (30 mL, V:V = 10:1 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography (eluent: B system) to obtain N 2 -(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-8-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)quinazoline-2,5-diamine 2 (0.28 g), yield: 67%.

[0149] MS m / z(ESI):454.2[M+1].

[0150] 1HNMR (400MHz, DMSO-d6) δ9.65(s,1H),9.47(s,1H),7.76(s,1H),7.27-7.33(m,3H),6.94(d,J=8.4Hz,1H),6.52(d,J=8.0Hz,1H),6.38(s,2 H),5.52(s,1H),4.27-4.37(m,2H),3.72-3.74(m,2H),3.40-3.43(m,2H),3.07-3.09(m,2H),2.84-2.86(m,2H),2.71(s,3H),1.81(s,3H).

[0151] Example 3

[0152] (2-(5-amino-2-((2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)quinazolin-8-yl)phenyl)methanol

[0153] first step

[0154] (2-(2-Amino-5-chloroquinazolin-8-yl)phenyl)methanol

[0155] 8-Bromo-5-chloroquinazolin-2-amine 1c (0.5 g, 1.93 mmol) and (2-(hydroxymethyl)phenyl)boronic acid 3a (0.32 g, 2.13 mmol, commercially available) were dissolved in 1,4-dioxane / water (20 mL / 4 mL). [1,1'-Bis(diphenylphosphino)ferrocene]palladium dichloride (0.32 g, 0.38 mmol) and potassium carbonate (0.80 g, 5.8 mmol) were added sequentially. The mixture was heated to 80°C for 4.5 hours. The mixture was cooled, filtered, and the filter cake was rinsed with a mixture of dichloromethane and methanol (33 mL, V:V = 10:1). The organic phase was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: System B) to afford (2-(2-amino-5-chloroquinazolin-8-yl)phenyl)methanol 3b (0.44 g) in 80% yield.

[0156] MS m / z(ESI):286.1[M+1]

[0157] Step 2

[0158] (2-(5-Chloro-2-((2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)quinazolin-8-yl)phenyl)methanol

[0159] (2-(2-Amino-5-chloroquinazolin-8-yl)phenyl)methanol 3b (0.7 g, 2.45 mmol) and 7-bromo-2-methyl-1,2,3,4-tetrahydroisoquinoline 1f (1.0 g, 4.41 mmol) were dissolved in 1,4-dioxane (30 mL), and tris(dibenzylideneacetone)dipalladium (0.45 g, 0.49 mmol), 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene (0.28 g, 0.49 mmol) and cesium carbonate (2.39 g, 7.35 mmol) were added in sequence, and the reaction was heated to 90 °C for 5 hours. The mixture was cooled, filtered, and the filter cake was washed. The organic phase was concentrated under reduced pressure, and the residue was separated and purified by silica gel column chromatography (eluent: System B) to give (2-(5-chloro-2-((2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)quinazolin-8-yl)phenyl)methanol 3c (0.26 g) in a yield of 25%.

[0160] MS m / z(ESI):431.2[M+1]

[0161] Step 3

[0162] tert-Butyl (8-(2-(hydroxymethyl)phenyl)-2-((2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)quinazolin-5-yl)carbamate

[0163] (2-(5-chloro-2-((2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)quinazolin-8-yl)phenyl)methanol 3c (0.17 g, 0.40 mmol) was dissolved in 1,4-dioxane (20 mL), and tert-butyl carbamate (0.47 g, 4.04 mmol), tris(dibenzylideneacetone)dipalladium (0.15 g, 0.16 mmol), 2-(dicyclohexylphosphine)3,6-dimethoxy-2',4',6'-triisopropyl-1,1'-biphenyl (0.086 g, 0.16 mmol), cesium carbonate (0.39 g, 1.21 mmol) and The mixture was reacted at 100°C for 5 hours, cooled, filtered, and the filter cake was washed. The organic phase was concentrated under reduced pressure to obtain tert-butyl 8-(2-(hydroxymethyl)phenyl)-2-((2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)quinazolin-5-yl)carbamate 3d (0.20 g), which was used in the next step without purification.

[0164] MS m / z(ESI):512.3[M+1]

[0165] Step 4

[0166] (2-(5-amino-2-((2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)quinazolin-8-yl)phenyl)methanol

[0167] Tert-butyl (8-(2-(hydroxymethyl)phenyl)-2-((2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)quinazolin-5-yl)carbamate 3d (0.20 g, 3.941 mmol) was dissolved in 1,4-dioxane (15 mL), and a solution of hydrogen chloride in 1,4-dioxane (3 mL, 4 M) was added, and the mixture was stirred at room temperature for 16 hours. The reaction solution was alkalized to about pH = 10 by adding 20% ​​aqueous sodium hydroxide solution dropwise. The mixture was extracted with a mixed solvent of dichloromethane and methanol (V:V = 10:1) (100 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting residue was separated and purified by silica gel column chromatography (eluent: System B) to give (2-(5-amino-2-((2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)quinazolin-8-yl)phenyl)methanol 3 (56 mg) in a two-step yield of 34%.

[0168] MS m / z(ESI):412.2[M+1]

[0169] 1HNMR(400MHz,DMSO-d6)δ9.52(s,1H),9.46(s,1H),7.59-7.65(m,2H),7.37-7.4 3(m,1H),7.29-7.34(m,2H),7.14-7.19(m,2H),6.80(d,J=8.4Hz,1H),6.51(d,J= 8.0Hz,1H),6.36(s,2H),4.86(t,J=4.8Hz,1H),4.34-4.36(m,1H),4.16-4.18(m, 1H),3.11-3.17(m,1H),3.01-3.03(m,1H),2.67(s,2H),2.53(s,2H),2.35(s,3H).

[0170] Example 4

[0171] 8-(2-Fluoro-6-methylphenyl)-N 2 -(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)quinazoline-2,5-diamine

[0172] first step

[0173] 5-Chloro-8-(2-fluoro-6-methylphenyl)quinazolin-2-amine

[0174] 8-Bromo-5-chloroquinazolin-2-amine 1c (0.6 g, 2.32 mmol) and (2-fluoro-6-methylphenyl)boronic acid 4a (0.5 g, 3.25 mmol, commercially available) were dissolved in 1,4-dioxane / water (20 mL / 4 mL). [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (0.38 g, 0.46 mmol) and potassium carbonate (0.96 g, 6.96 mmol) were added sequentially. The mixture was heated to 90°C for 9 hours. After cooling and filtration, the filter cake was rinsed with a mixture of dichloromethane and methanol (33 mL, V:V = 10:1). The organic phase was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: System A) to afford 5-chloro-8-(2-fluoro-6-methylphenyl)quinazolin-2-amine 4b (0.24 g) in a 36% yield.

[0175] MS m / z(ESI):288.1[M+1]

[0176] Step 2

[0177] 5-Chloro-8-(2-fluoro-6-methylphenyl)-N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)quinazolin-2-amine

[0178] 5-Chloro-8-(2-fluoro-6-methylphenyl)quinazolin-2-amine 4b (0.24 g, 0.83 mmol) and 7-bromo-2-methyl-1,2,3,4-tetrahydroisoquinoline 1f (0.37 g, 1.66 mmol) were dissolved in 1,4-dioxane (20 mL). Tris(dibenzylideneacetone)dipalladium (0.16 g, 0.17 mmol), 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene (0.098 g, 0.17 mmol) and cesium carbonate (0.81 g, 2.49 mmol) were added in sequence and heated to 90 °C for 5 hours. The mixture was cooled, filtered, and the filter cake was washed. The organic phase was concentrated under reduced pressure, and the residue was separated and purified by silica gel column chromatography (eluent: System B) to give 5-chloro-8-(2-fluoro-6-methylphenyl)-N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)quinazolin-2-amine 4c (0.14 g) in a yield of 33%.

[0179] MS m / z(ESI):433.2[M+1]

[0180] Step 3

[0181] tert-Butyl (8-(2-fluoro-6-methylphenyl)-2-((2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)quinazolin-5-yl)carbamate

[0182] 5-Chloro-8-(2-fluoro-6-methylphenyl)-N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)quinazolin-2-amine 4c (0.14 g, 0.32 mmol) was dissolved in 1,4-dioxane (10 mL), and tert-butyl carbamate (0.38 g, 3.23 mmol), tris(dibenzylideneacetone)dipalladium (0.12 g, 0.13 mmol), 2-(dicyclohexylphosphine)3,6-dimethoxy-2',4',6'-triisopropyl-1,1'-biphenyl (0.069 g, 0.13 mmol), cesium carbonate (0.32 g, 0.97 mmol) and The mixture was reacted at 100°C for 4 hours with the addition of 1% zeolite (0.20 g) of 4-methylenediaminetetrahydroisoquinolin-7-yl)methylenediamine (0.20 g). The mixture was cooled, filtered, and the filter cake was washed. The organic phase was concentrated under reduced pressure to afford tert-butyl 8-(2-fluoro-6-methylphenyl)-2-((2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)quinazolin-5-yl)carbamate 4d (0.17 g), which was used directly in the next step without purification.

[0183] MS m / z(ESI):514.3[M+1]

[0184] Step 4

[0185] 8-(2-Fluoro-6-methylphenyl)-N 2 -(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)quinazoline-2,5-diamine

[0186] Tert-butyl (8-(2-fluoro-6-methylphenyl)-2-((2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)quinazolin-5-yl)carbamate 4d (0.17 g) was dissolved in 1,4-dioxane (15 mL). A 1,4-dioxane solution of hydrogen chloride (3 mL, 4 M) was added, and the mixture was stirred at room temperature for 20 hours. A 20% aqueous sodium hydroxide solution was added dropwise to alkalize the reaction mixture to a pH of approximately 10. The mixture was then extracted with a mixed solvent of dichloromethane and methanol (V:V = 10:1) (100 mL x 3), dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting residue was purified by silica gel column chromatography (eluent: System B) to afford 8-(2-fluoro-6-methylphenyl)-N 2 -(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)quinazoline-2,5-diamine 4 (50 mg), two-step yield: 37%.

[0187] MS m / z(ESI):414.3[M+1]

[0188] 1HNMR(400MHz,DMSO-d6)δ9.53(s,1H),9.46(s,1H),7.55(s,1H),7.28-7.35(m,2H),7.16-7.21(m,2H),7.08-7.13(m,1H),6.79(d,J =8.0Hz,1H),6.53(d,J=8.0Hz,1H),6.41(s,2H),3.03-3.15(m,2H),2.66-2.68(m,2H),2.52-2.54(m,2H),2.36(s,3H),2.03(s,3H).

[0189] Example 5

[0190] N 2 -(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-8-(4-methylpyridin-3-yl)quinazoline-2,5-diamine

[0191] first step

[0192] 5-Chloro-8-(4-methylpyridin-3-yl)quinazolin-2-amine

[0193] 8-Bromo-5-chloroquinazolin-2-amine 1c (1.5 g, 5.80 mmol) and 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine 5a (1.4 g, 6.38 mmol) were dissolved in a mixed solvent of 1,4-dioxane and water (22 mL, V:V = 10:1). [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (0.24 g, 0.29 mmol) and potassium carbonate (2.41 g, 17.41 mmol) were added sequentially, and the mixture was heated to 60°C for 6 hours. The mixture was cooled, diluted with water, extracted with a mixed solvent of dichloromethane and methanol (V:V = 10:1) (100 mL × 3), dried over anhydrous sodium sulfate, filtered, and the organic phase was concentrated under reduced pressure. The resulting residue was separated and purified by silica gel column chromatography (eluent: System A) to give 5-chloro-8-(4-methylpyridin-3-yl)quinazolin-2-amine 5b (1.27 g) in a yield of 80.8%.

[0194] MS m / z(ESI):271.1[M+1]

[0195] Step 2

[0196] 5-Chloro-N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-8-(4-methylpyridin-3-yl)quinazolin-2-amine

[0197] 5-Chloro-8-(4-methylpyridin-3-yl)quinazolin-2-amine 5b (0.5 g, 1.85 mmol) and 7-bromo-2-methyl-1,2,3,4-tetrahydroisoquinoline 1f (0.5 g, 2.22 mmol) were dissolved in 1,4-dioxane (15 mL). Tris(dibenzylideneacetone)dipalladium (0.17 g, 0.18 mmol), 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene (0.11 g, 0.18 mmol) and cesium carbonate (1.81 g, 5.54 mmol) were added in sequence and heated to 100 °C for 6 h. The mixture was cooled, filtered, and the filter cake was washed. The organic phase was concentrated under reduced pressure. The residue was chromatographed on a silica gel column (eluent: System B) to give 5-chloro-N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-8-(4-methylpyridin-3-yl)quinazolin-2-amine 5c (0.34 g) in a yield of 44%.

[0198] MS m / z(ESI):416.2[M+1]

[0199] Step 3

[0200] tert-Butyl (2-((2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)-8-(4-methylpyridin-3-yl)quinazolin-5-yl)carbamate

[0201] 5-Chloro-N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-8-(4-methylpyridin-3-yl)quinazolin-2-amine 5c (0.29 g, 0.70 mmol) was dissolved in 1,4-dioxane (20 mL), and tert-butyl carbamate (1.23 g, 10.46 mmol), tris(dibenzylideneacetone)dipalladium (0.064 g, 0.070 mmol), 2-(dicyclohexylphosphine)3,6-dimethoxy-2',4',6'-triisopropyl-1,1'-biphenyl (0.075 g, 0.14 mmol), cesium carbonate (0.68 g, 2.09 mmol) and The mixture was reacted at 90°C for 6 hours with the addition of 2-methylenediamine zeolite (0.29 g). The mixture was cooled, filtered, and the filter cake was washed. The organic phase was concentrated under reduced pressure, and the resulting residue was separated and purified by silica gel column chromatography (eluent: System B) to give tert-butyl (2-((2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)-8-(4-methylpyridin-3-yl)quinazolin-5-yl)carbamate 5d (0.25 g) in a yield of 72%.

[0202] MS m / z(ESI):497.3[M+1]

[0203] Step 4

[0204] N2 -(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-8-(4-methylpyridin-3-yl)quinazoline-2,5-diamine

[0205] Tert-butyl (2-((2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)-8-(4-methylpyridin-3-yl)quinazolin-5-yl)carbamate 5d (0.25 g, 0.5 mmol) was dissolved in dichloromethane (15 mL), trifluoroacetic acid (3 mL) was added, and the mixture was stirred at room temperature for 12 hours. 20% aqueous sodium hydroxide solution was added dropwise to alkalize the reaction solution to a pH of about 10, and the mixture was extracted with a mixed solvent of dichloromethane and methanol (V:V=10:1) (100 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting residue was separated and purified by silica gel column chromatography (eluent: System B) to obtain N 2 -(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-8-(4-methylpyridin-3-yl)quinazoline-2,5-diamine 5 (0.12 g), yield: 60%.

[0206] MS m / z(ESI):397.3[M+1]

[0207] 1 HNMR(400MHz,DMSO-d6)δ9.58(s,1H),9.49(s,1H),8.47(d,J=4.8Hz,1H),8.36(s,1H),7.57(s,1H),7.35-7.39(m,2H),7.20(d,J=8.4Hz,1 H),6.83(d,J=8.4Hz,1H),6.56(d,J=8.0Hz,1H),6.47(s,2H),3.13(s,2H),2.67-2.70(m,2H),2.54-2.57(m,2H),2.38(s,3H),2.11(s,3H).

[0208] Example 6

[0209] N 2 -(6-methyl-5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)-8-(4-methylpyridin-3-yl)quinazoline-2,5-diamine

[0210] first step

[0211] 2,5-Dichloro-8-(4-methylpyridin-3-yl)quinazoline

[0212] 5-Chloro-8-(4-methylpyridin-3-yl)quinazolin-2-amine 5b (1.15 g, 4.25 mmol) was dissolved in a mixed solvent of dichloromethane (10 mL) and N,N-dimethylformamide (1 mL). Tetrabutylammonium chloride (1.42 g, 5.10 mmol) was added, followed by slow dropwise addition of tert-butyl nitrite 6a (1.31 g, 12.74 mmol, commercially available) and trimethylsilyl chloride (1.85 g, 16.99 mmol). The mixture was stirred at 50°C under nitrogen for 3 hours. The mixture was cooled, diluted with dichloromethane, filtered, and washed to obtain 2,5-dichloro-8-(4-methylpyridin-3-yl)quinazoline 6b (1.0 g) in an 81% yield.

[0213] MS m / z(ESI):290.1[M+1]

[0214] Step 2

[0215] 5-Chloro-N-(6-methyl-5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)-8-(4-methylpyridin-3-yl)quinazolin-2-amine

[0216] 2,5-Dichloro-8-(4-methylpyridin-3-yl)quinazoline 6b (0.3 g, 1.03 mmol) and 6-methyl-5,6,7,8-tetrahydro-1,6-naphthyridin-3-amine 6c (0.17 g, 1.03 mmol) were dissolved in 1,4-dioxane (15 mL). Palladium acetate (69.6 mg, 0.31 mol), 4,5-bis(diphenylphosphino-9,9-dimethylxanthene) (0.15 g, 0.26 mol) and cesium carbonate (0.67 g, 2.07 mmol) were added in sequence. The mixture was heated to 100°C in a microwave oven for 1 hour. The mixture was cooled, filtered, and the filter cake was washed. The organic phase was concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent: System B) to give 5-chloro-N-(6-methyl-5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)-8-(4-methylpyridin-3-yl)quinazolin-2-amine 6d (0.4 g) in a yield of 93%.

[0217] MS m / z(ESI):417.1[M+1]

[0218] Step 3

[0219] tert-Butyl 2-((6-methyl-5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)amino)-8-(4-methylpyridin-3-yl)quinazolin-5-yl)carbamate

[0220] 5-Chloro-N-(6-methyl-5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)-8-(4-methylpyridin-3-yl)quinazolin-2-amine 6d (0.38 g, 0.90 mmol) was dissolved in 1,4-dioxane (40 mL), and tert-butyl carbamate (1.58 g, 13.5 mmol), tris(dibenzylideneacetone)dipalladium (0.12 g, 0.18 mmol), 2-(dicyclohexylphosphine)3,6-dimethoxy-2',4',6'-triisopropyl-1,1'-biphenyl (0.096 g, 0.18 mmol), cesium carbonate (0.88 g, 2.7 mmol) and The mixture was reacted at 90°C for 6.5 hours with the addition of 1% zeolite (0.40 g) of 4-methylenediaminetetrahydro-1,6-naphthyridin-3-yl)amino-8-(4-methylpyridin-3-yl)quinazolin-5-yl)carbamic acid tert-butyl ester 6e (0.25 g) in a 55.8% yield. The mixture was cooled, filtered, and the filter cake was washed. The organic phase was concentrated under reduced pressure, and the resulting residue was separated and purified by silica gel column chromatography (eluent: System B) to obtain tert-butyl 2-((6-methyl-5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)amino)-8-(4-methylpyridin-3-yl)quinazolin-5-yl)carbamate 6e (0.25 g).

[0221] MS m / z(ESI):498.3[M+1]

[0222] Step 4

[0223] N 2 -(6-methyl-5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)-8-(4-methylpyridin-3-yl)quinazoline-2,5-diamine

[0224] Tert-butyl 2-((6-methyl-5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)amino)-8-(4-methylpyridin-3-yl)quinazolin-5-yl)carbamate 6e (0.25 g, 0.5 mmol) was dissolved in dichloromethane (15 mL), trifluoroacetic acid (3 mL) was added, and the mixture was stirred at room temperature for 12 hours. 20% aqueous sodium hydroxide solution was added dropwise to alkalize the reaction solution to a pH of approximately 10, and the mixture was extracted with a mixed solvent of dichloromethane and methanol (V:V = 10:1) (100 mL × 3), dried over anhydrous sodium sulfate, filtered, and the organic phase was concentrated under reduced pressure. The resulting residue was separated and purified by silica gel column chromatography (eluent: System B) to obtain N 2 -(6-methyl-5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)-8-(4-methylpyridin-3-yl)quinazoline-2,5-diamine 6 (0.07 g), yield: 35%.

[0225] MS m / z(ESI):398.3[M+1]

[0226] 1HNMR (400MHz, DMSO-d6) δ9.80 (s, 1H), 9.52 (s, 1H), 8.46 (d, J = 4.8Hz, 1H), 8.32-8.35 (m, 2H),7.93(s,1H),7.36-7.39(m,2H),6.57(d,J=8.0Hz,1H),6.49(s,2H),3. 09(s,2H),2.73-2.76(m,2H),2.60-2.63(m,2H),2.38(s,3H),2.07(s,3H).

[0227] Example 7

[0228] N 2 -(6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-8-(4-methylpyridin-3-yl)quinazoline-2,5-diamine

[0229] first step

[0230] 5-Chloro-N-(6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-8-(4-methylpyridin-3-yl)quinazolin-2-amine

[0231] 2,5-Dichloro-8-(4-methylpyridin-3-yl)quinazoline 6b (0.4 g, 1.38 mmol) and 6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-amine 7a (795.14 mg, 4.14 mmol, commercially available) were dissolved in n-butanol (20 mL). Two drops of concentrated sulfuric acid were added dropwise and the mixture was heated at 120°C in a microwave oven for 2 hours. The mixture was cooled and concentrated under reduced pressure to remove the n-butanol. The resulting residue was purified by silica gel column chromatography (eluent: System B) to afford 5-chloro-N-(6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-8-(4-methylpyridin-3-yl)quinazoline-2-amine 7b (0.45 g) in a 73% yield.

[0232] MS m / z(ESI):446.2[M+1]

[0233] Step 2

[0234] tert-Butyl (2-((6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)-8-(4-methylpyridin-3-yl)quinazolin-5-yl)carbamate

[0235] 5-Chloro-N-(6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-8-(4-methylpyridin-3-yl)quinazolin-2-amine 7b (0.40 g, 0.90 mmol) was dissolved in 1,4-dioxane (50 mL), and tert-butyl carbamate (1.58 g, 13.5 mmol), tris(dibenzylideneacetone)dipalladium (0.12 g, 0.18 mmol), 2-(dicyclohexylphosphine)3,6-dimethoxy-2',4',6'-triisopropyl-1,1'-biphenyl (0.096 g, 0.18 mmol), cesium carbonate (0.88 g, 2.7 mmol) and The mixture was reacted at 90°C for 7.5 hours with the addition of 0.5% paraformaldehyde (0.40 g) of 4-methylenediamine zeolite (2-methylenediamine) and 0.5% paraformaldehyde (0.5 g). The mixture was cooled, filtered, and the filter cake was washed. The organic phase was concentrated under reduced pressure, and the resulting residue was separated and purified by silica gel column chromatography (eluent: System B) to give tert-butyl (2-((6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)-8-(4-methylpyridin-3-yl)quinazolin-5-yl)carbamate 7c (0.43 g) in a 91% yield.

[0236] MS m / z(ESI):527.3[M+1]

[0237] Step 3

[0238] N 2 -(6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-8-(4-methylpyridin-3-yl)quinazoline-2,5-diamine

[0239] Tert-butyl (2-((6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)-8-(4-methylpyridin-3-yl)quinazolin-5-yl)carbamate 7c (0.40 g) was dissolved in dichloromethane (40 mL), trifluoroacetic acid (5 mL) was added, and the mixture was stirred at room temperature for 12 hours. 20% aqueous sodium hydroxide solution was added dropwise to alkalize the reaction solution to a pH of about 10, and the mixture was extracted with a mixed solvent of dichloromethane and methanol (V:V=10:1) (100 mL×3), dried over anhydrous sodium sulfate, filtered, and the organic phase was concentrated under reduced pressure. The resulting residue was separated and purified by silica gel column chromatography (eluent: System B) to obtain N 2 -(6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-8-(4-methylpyridin-3-yl)quinazoline-2,5-diamine 7 (0.04 g), yield: 12%.

[0240] MS m / z(ESI):427.2[M+1].

[0241] 1HNMR(400MHz,DMSO-d6)δ9.48(s,1H),8.46(d,J=4.0Hz,1H),8.34(s,1H),7.81(s,1H),7.75(s,1H),7.36-7.39(m,2H), 6.69(s,1H),6.58(d,J=8.0Hz,1H),6.49(s,2H),3.83(s,3H),2.96(s,2H),2.69-2.71(m,2H),2.35(s,3H),2.09(s,3H).

[0242] Example 8

[0243] N 2 -(4-(4-methylpiperazin-1-yl)phenyl)-8-(4-methylpyridin-3-yl)quinazoline-2,5-diamine

[0244] first step

[0245] 5-Chloro-N-(4-(4-methylpiperazin-1-yl)phenyl)-8-(4-methylpyridin-3-yl)quinazolin-2-amine

[0246] 2,5-Dichloro-8-(4-methylpyridin-3-yl)quinazoline 6b (0.2 g, 0.69 mmol) and 4-(4-methylpiperazin-1-yl)aniline 8a (0.15 g, 0.76 mmol) were dissolved in isopropanol (12 mL), trifluoroacetic acid (0.15 mL) was added, and the mixture was heated to 100°C in a sealed tube for 7.5 hours. The reaction mixture was cooled to room temperature, and a saturated sodium bicarbonate solution was added dropwise to neutralize the mixture. The mixture was extracted with a mixed solvent of dichloromethane and methanol (V:V = 10:1) (30 mL × 3). The organic phase was dried over anhydrous sodium sulfate and filtered. The organic phase was concentrated under reduced pressure. The resulting residue was separated and purified by silica gel column chromatography (eluent: System B) to give 5-chloro-N-(4-(4-methylpiperazin-1-yl)phenyl)-8-(4-methylpyridin-3-yl)quinazolin-2-amine 8b (0.30 g) in a yield of 97.8%.

[0247] MS m / z(ESI):445.2[M+1]

[0248] Step 2

[0249] tert-Butyl (2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-8-(4-methylpyridin-3-yl)quinazolin-5-yl)carbamate

[0250] 5-Chloro-N-(4-(4-methylpiperazin-1-yl)phenyl)-8-(4-methylpyridin-3-yl)quinazolin-2-amine 8b (0.30 g, 0.67 mmol) was dissolved in 1,4-dioxane (30 mL), and tert-butyl carbamate (1.38 g, 11.8 mmol), tris(dibenzylideneacetone)dipalladium (0.11 g, 0.16 mmol), 2-(dicyclohexylphosphine)3,6-dimethoxy-2',4',6'-triisopropyl-1,1'-biphenyl (0.084 g, 0.16 mmol), cesium carbonate (0.77 g, 2.36 mmol) and The mixture was reacted at 90°C for 6.5 hours with the addition of 1% zeolite (0.35 g) and 4% zeolite (0.35 g). The mixture was cooled, filtered, and the filter cake was washed. The organic phase was concentrated under reduced pressure, and the resulting residue was separated and purified by silica gel column chromatography (eluent: System B) to give tert-butyl (2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-8-(4-methylpyridin-3-yl)quinazolin-5-yl)carbamate 8c (0.24 g) in a 68% yield.

[0251] MS m / z(ESI):526.3[M+1]

[0252] Step 3

[0253] N 2 -(4-(4-methylpiperazin-1-yl)phenyl)-8-(4-methylpyridin-3-yl)quinazoline-2,5-diamine

[0254] Tert-butyl (2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-8-(4-methylpyridin-3-yl)quinazolin-5-yl)carbamate 8c (0.24 g) was dissolved in dichloromethane (10 mL), trifluoroacetic acid (3 mL) was added, and the mixture was stirred at room temperature for 12 hours. 20% aqueous sodium hydroxide solution was added dropwise to alkalize the reaction solution to a pH of about 10, and the mixture was extracted with a mixed solvent of dichloromethane and methanol (V:V=10:1) (30 mL×3), dried over anhydrous sodium sulfate, filtered, and the organic phase was concentrated under reduced pressure. The resulting residue was separated and purified by silica gel column chromatography (eluent: System B) to obtain N 2 -(4-(4-methylpiperazin-1-yl)phenyl)-8-(4-methylpyridin-3-yl)quinazoline-2,5-diamine 8 (0.15 g), yield: 88%.

[0255] MS m / z(ESI):426.2[M+1]

[0256] 1HNMR(400MHz,DMSO-d6)δ9.43(s,1H),9.41(s,1H),8.46(d,J=4.8Hz,1H),8.32(s,1H),7.47(d,J=8.8Hz,2H),7.35-7.38(m,2 H),6.62(d,J=8.8Hz,2H),6.51(d,J=8.0Hz,1H),6.40(s,2H),3.16-3.18(m,1H),2.98-3.01(m,4H),2.25(s,3H),2.09(s,3H).

[0257] Example 9

[0258] N 2 -(3-((dimethylamino)methyl)-4-(tetrahydro-2H-pyran-4-yl)phenyl)-8-(4-methylpyridin-3-yl)quinazoline-2,5-diamine

[0259] first step

[0260] 8-Bromo-2,5-dichloroquinazoline

[0261] 8-Bromo-5-chloroquinazolin-2-amine 1c (4.8 g, 18.6 mmol) was dissolved in a mixture of dichloromethane (50 mL) and N,N-dimethylformamide (10 mL). Tetrabutylammonium chloride (6.19 g, 22.28 mmol) was added, followed by the slow dropwise addition of tert-butyl nitrite 6a (5.74 g, 55.71 mmol) and trimethylsilyl chloride (8.07 g, 74.27 mmol). The reaction was stirred at 50°C under nitrogen for 5 hours. The mixture was cooled, concentrated under reduced pressure, and water was added to precipitate a solid. The solid was filtered under reduced pressure, washed, and dried to afford 8-bromo-2,5-dichloroquinazoline 9a (4.3 g) in an 83% yield.

[0262] 1 HNMR (400MHz, DMSO-d6) δ9.76 (s, 1H), 8.44 (d, J = 8.0Hz, 1H), 7.88 (d, J = 8.0Hz, 1H).

[0263] Step 2

[0264] 8-Bromo-5-chloro-N-(3-((dimethylamino)methyl)-4-(tetrahydro-2H-pyran-4-yl)phenyl)quinazolin-2-amine

[0265] 8-Bromo-2,5-dichloroquinazoline 9a (0.55 g, 1.98 mmol) and 3-((dimethylamino)methyl)-4-(tetrahydro-2H-pyran-4-yl)aniline 9b (0.46 g, 1.98 mmol, commercially available) were dissolved in n-butanol (35 mL). Trifluoroacetic acid (0.25 mL) was added, and the mixture was heated to 100°C in a sealed tube for 6 hours. After cooling to room temperature, the mixture was concentrated under reduced pressure to remove the n-butanol. The resulting residue was purified by silica gel column chromatography (eluent: System B) to afford 8-bromo-5-chloro-N-(3-((dimethylamino)methyl)-4-(tetrahydro-2H-pyran-4-yl)phenyl)quinazolin-2-amine 9c (0.42 g) in a 44.6% yield.

[0266] MS m / z(ESI):475.1[M+1]

[0267] Step 3

[0268] 5-Chloro-N-(3-((dimethylamino)methyl)-4-(tetrahydro-2H-pyran-4-yl)phenyl)-8-(4-methylpyridin-3-yl)quinazolin-2-amine

[0269] 8-Bromo-5-chloro-N-(3-((dimethylamino)methyl)-4-(tetrahydro-2H-pyran-4-yl)phenyl)quinazolin-2-amine 9c (0.39 g, 0.82 mmol) and 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine 5a (0.22 g, 0.23 mmol) were dissolved in a mixed solvent of 1,4-dioxane and water (22 mL, V:V=10:1). [1,1'-Bis(diphenylphosphino)ferrocene]palladium dichloride (0.12 g, 0.16 mmol) and potassium carbonate (0.34 g, 2.46 mmol) were added sequentially, and the mixture was heated to 90°C for 3.5 hours. The reaction mixture was cooled, diluted with water, extracted with a mixed solvent of dichloromethane and methanol (V:V=10:1) (30 mL×3), dried over anhydrous sodium sulfate, filtered, and the organic phase was concentrated under reduced pressure. The resulting residue was separated and purified by silica gel column chromatography (eluent: System B) to give 5-chloro-N-(3-((dimethylamino)methyl)-4-(tetrahydro-2H-pyran-4-yl)phenyl)-8-(4-methylpyridin-3-yl)quinazolin-2-amine 9d (0.4 g) in a 100% yield.

[0270] MS m / z(ESI):488.2[M+1]

[0271] Step 4

[0272] tert-Butyl (2-((3-((dimethylamino)methyl)-4-(tetrahydro-2H-pyran-4-yl)phenyl)amino)-8-(4-methylpyridin-3-yl)quinazolin-5-yl)carbamate

[0273] 5-Chloro-N-(3-((dimethylamino)methyl)-4-(tetrahydro-2H-pyran-4-yl)phenyl)-8-(4-methylpyridin-3-yl)quinazolin-2-amine 9d (0.38 g, 0.78 mmol) was dissolved in 1,4-dioxane (40 mL), and tert-butyl carbamate (1.37 g, 11.7 mmol), tris(dibenzylideneacetone)dipalladium (0.14 g, 0.16 mmol), 2-(dicyclohexylphosphine)3,6-dimethoxy-2',4',6'-triisopropyl-1,1'-biphenyl (0.084 g, 0.16 mmol), cesium carbonate (0.76 g, 2.34 mmol) and The mixture was reacted at 90°C for 8 hours with 1% paraformaldehyde (0.2 g) and 2% paraformaldehyde (0.3 g). The mixture was cooled, filtered, and the filter cake was washed. The organic phase was concentrated under reduced pressure, and the resulting residue was separated and purified by silica gel column chromatography (eluent: System B) to give tert-butyl (2-((3-((dimethylamino)methyl)-4-(tetrahydro-2H-pyran-4-yl)phenyl)amino)-8-(4-methylpyridin-3-yl)quinazolin-5-yl)carbamate 9e (0.4 g) in a 90% yield.

[0274] MS m / z(ESI):569.4[M+1]

[0275] Step 5

[0276] N 2 -(3-((dimethylamino)methyl)-4-(tetrahydro-2H-pyran-4-yl)phenyl)-8-(4-methylpyridin-3-yl)quinazoline-2,5-diamine

[0277] Tert-butyl (2-((3-((dimethylamino)methyl)-4-(tetrahydro-2H-pyran-4-yl)phenyl)amino)-8-(4-methylpyridin-3-yl)quinazolin-5-yl)carbamate 9e (0.20 g) was dissolved in dichloromethane (25 mL), trifluoroacetic acid (3 mL) was added, and the mixture was stirred at room temperature for 18 hours. 20% aqueous sodium hydroxide solution was added dropwise to alkalize the reaction solution to a pH of about 10, and the mixture was extracted with a mixed solvent of dichloromethane and methanol (V:V=10:1) (30 mL×3), dried over anhydrous sodium sulfate, filtered, and the organic phase was concentrated under reduced pressure. The resulting residue was separated and purified by silica gel column chromatography (eluent: System B) to obtain N 2-(3-((dimethylamino)methyl)-4-(tetrahydro-2H-pyran-4-yl)phenyl)-8-(4-methylpyridin-3-yl)quinazoline-2,5-diamine 9 (0.11 g), yield: 65%.

[0278] MS m / z(ESI):469.3[M+1]

[0279] 1 HNMR(400MHz,DMSO-d6)δ9.61(s,1H),9.50(s,1H),8.46(s,1H),8.15(s, 1H),7.62(s,1H),7.48(d,J=8.0Hz,1H),7.34-7.38(m,2H),7.02(d,J=8.4 Hz,1H),6.55(d,J=8.0Hz,1H),6.48(s,2H),3.90-3.94(m,2H),3.39-3.4 7(m,2H),3.01-3.08(m,2H),2.67(s,6H),2.09(s,3H),1.51-1.63(m,5H).

[0280] Example 10

[0281] N 2 -(3-((dimethylamino)methyl)-4-(tetrahydrofuran-3-yl)phenyl)-8-(4-methylpyridin-3-yl)quinazoline-2,5-diamine

[0282] first step

[0283] (2-(2,5-Dihydrofuran-3-yl)-5-nitrophenyl)methanol

[0284] (2-Bromo-5-nitrophenyl)methanol 10a (0.70 g, 3.02 mmol, commercially available) and 2-(2,5-dihydrofuran-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 10b (0.65 g, 3.32 mmol, commercially available) were dissolved in 1,4-dioxane (15 mL), and 1,1-bis(diphenylphosphine)dichloroferric palladium (110 mg, 0.01 The reaction mixture was heated to 80°C, reacted for 4 hours, cooled, and filtered under reduced pressure. The filter cake was washed with dichloromethane, and the organic phase was concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent: System B) to give (2-(2,5-dihydrofuran-3-yl)-5-nitrophenyl)methanol 10c (0.66 g) in a yield of 99%.

[0285] MS m / z(ESI):222.1[M+1]

[0286] Step 2

[0287] (5-Amino-2-(tetrahydrofuran-3-yl)phenyl)methanol

[0288] (2-(2,5-dihydrofuran-3-yl)-5-nitrophenyl)methanol 10c (0.65 g, 2.94 mmol) was dissolved in anhydrous methanol (20 mL), and palladium / carbon (10%, 0.20 g) was added. The mixture was reacted at room temperature under a hydrogen atmosphere for 15 hours. After completion of the reaction, the reaction solution was filtered through celite, the filter cake was washed with anhydrous methanol, and the organic phase was concentrated under reduced pressure to provide (5-amino-2-(tetrahydrofuran-3-yl)phenyl)methanol 10d (0.57 g) in a 99% yield.

[0289] MS m / z(ESI):194.1[M+1]

[0290] Step 3

[0291] (5-((5-chloro-8-(4-methylpyridin-3-yl)quinazolin-2-yl)amino)-2-(tetrahydrofuran-3-yl)phenyl)methanol

[0292] 2,5-Dichloro-8-(4-methylpyridin-3-yl)quinazoline 6b (0.5 g, 1.72 mmol) and (5-amino-2-(tetrahydrofuran-3-yl)phenyl)methanol 10d (0.33 g, 1.72 mmol) were dissolved in n-butanol (10 mL), and trifluoroacetic acid (0.20 g, 1.72 mmol) was added. The reaction mixture was heated to 100°C, reacted for 5 hours, then cooled, filtered under reduced pressure, washed with dichloromethane, and the organic phase was concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent: System B) to give (5-((5-chloro-8-(4-methylpyridin-3-yl)quinazolin-2-yl)amino)-2-(tetrahydrofuran-3-yl)phenyl)methanol 10e (0.52 g) in a yield of 68%.

[0293] MS m / z(ESI):447.1[M+1]

[0294] Step 4

[0295] 5-Chloro-N-(3-(chloromethyl)-4-(tetrahydrofuran-3-yl)phenyl)-8-(4-methylpyridin-3-yl)quinazolin-2-amine

[0296] (5-((5-chloro-8-(4-methylpyridin-3-yl)quinazolin-2-yl)amino)-2-(tetrahydrofuran-3-yl)phenyl)methanol 10e (0.49 g, 1.10 mmol) and N,N-dimethylformamide (8 mg, 0.011 mmol) were dissolved in dichloromethane (15 mL). Under an ice-water bath, thionyl chloride (0.26 g, 2.21 mmol) was added dropwise. After the reaction mixture returned to room temperature, the reaction was allowed to react for 4 hours. After the reaction, the reaction solution was diluted with water (20 mL), neutralized with saturated sodium bicarbonate solution (20 mL) until the solution became alkaline, and extracted with a mixed solvent of dichloromethane and methanol (V:V = 10:1) (30 mL × 3), washed with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The resulting residue was separated and purified by silica gel column chromatography (eluent: System B) to give 5-chloro-N-(3-(chloromethyl)-4-(tetrahydrofuran-3-yl)phenyl)-8-(4-methylpyridin-3-yl)quinazolin-2-amine 10f (0.51 g) in a yield of 99%.

[0297] MS m / z(ESI):465.1[M+1]

[0298] Step 5

[0299] 5-Chloro-N-(3-((dimethylamino)methyl)-4-(tetrahydrofuran-3-yl)phenyl)-8-(4-methylpyridin-3-yl)quinazolin-2-amine

[0300] 5-Chloro-N-(3-(chloromethyl)-4-(tetrahydrofuran-3-yl)phenyl)-8-(4-methylpyridin-3-yl)quinazolin-2-amine 10f (0.50 g, 1.07 mmol), dimethylamine hydrochloride (81 mg, 2.15 mmol), and cesium carbonate (1.05 g, 3.22 mmol) were dissolved in N,N-dimethylformamide (20 mL) and heated to 100°C for 2 hours. After cooling, the reaction solution was diluted with ethyl acetate, washed with water, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to afford 5-chloro-N-(3-((dimethylamino)methyl)-4-(tetrahydrofuran-3-yl)phenyl)-8-(4-methylpyridin-3-yl)quinazolin-2-amine 10 g (0.38 g) in a 75% yield.

[0301] MS m / z(ESI):474.2[M+1]

[0302] Step 6

[0303] tert-Butyl (2-((3-((dimethylamino)methyl)-4-(tetrahydrofuran-3-yl)phenyl)amino)-8-(4-methylpyridin-3-yl)quinazolin-5-yl)carbamate

[0304] 10 g (0.35 g, 0.74 mmol) of 5-chloro-N-(3-((dimethylamino)methyl)-4-(tetrahydrofuran-3-yl)phenyl)-8-(4-methylpyridin-3-yl)quinazolin-2-amine and tert-butyl carbamate (1.30 g, 11.80 mmol) were dissolved in 1,4-dioxane (10 mL). Tris(dibenzylideneacetone)dipalladium (135 mg, 0.15 mmol), 2-(dicyclohexylphosphine)3,6-dimethoxy-2',4',6'-triisopropyl-1,1'-biphenyl (79 mg, 0.15 mmol) and cesium carbonate (0.72 g, 2.22 mmol) were added sequentially. The reaction mixture was heated to 100 ° C for 4 hours. The reaction mixture was cooled, filtered, washed, and the organic phase was concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent: System B) to give tert-butyl (2-((3-((dimethylamino)methyl)-4-(tetrahydrofuran-3-yl)phenyl)amino)-8-(4-methylpyridin-3-yl)quinazolin-5-yl)carbamate 10h (197 mg) in a yield of 48%.

[0305] MS m / z(ESI):555.3[M+1]

[0306] Step 7

[0307] N 2 -(3-((dimethylamino)methyl)-4-(tetrahydrofuran-3-yl)phenyl)-8-(4-methylpyridin-3-yl)quinazoline-2,5-diamine

[0308] Tert-butyl (2-((3-((dimethylamino)methyl)-4-(tetrahydrofuran-3-yl)phenyl)amino)-8-(4-methylpyridin-3-yl)quinazolin-5-yl)carbamate 10h (0.19 g, 0.34 mmol) was dissolved in dichloromethane (15 mL), and trifluoroacetic acid (1.5 mL) was added dropwise. The mixture was reacted at room temperature for 22 hours. The reaction solution was diluted with water and neutralized with saturated sodium bicarbonate solution until the solution became weakly alkaline. The mixture was extracted with a mixed solvent of dichloromethane and methanol (V:V=10:1) (30 mL×3), washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent: System B) to obtain N 2 -(3-((dimethylamino)methyl)-4-(tetrahydrofuran-3-yl)phenyl)-8-(4-methylpyridin-3-yl)quinazoline-2,5-diamine 10 (116 mg), yield: 72%.

[0309] MS m / z(ESI):455.3[M+1]

[0310] 1H NMR (400MHz, DMSO-d6) δ9.61 (s, 1H), 9.49 (s, 1H), 8.47 (d, J = 5.2Hz, 1H), 8.39 ( s,1H),7.62(s,1H),7.46(d,J=7.6Hz,1H),7.34-7.37(m,2H),7.05(d,J=9.2Hz ,1H),6.55(d,J=8.0Hz,1H),6.48(s,2H),3.90-3.97(m,3H),3.73-3.80(m,1H) ,3.65-3.70(m,1H),3.41-3.45(m,2H),2.08-2.30(m,10H),1.76-1.85(m,1H).

[0311] Example 11

[0312] (R)-1-(5-((5-amino-8-(4-methylpyridin-3-yl)quinazolin-2-yl)amino)-2-(tetrahydro-2H-pyran-4-yl)benzyl)pyrrolidin-3-ol

[0313] first step

[0314] (R)-(2-Bromo-5-nitrophenyl)(3-hydroxypyrrolidin-1-yl)methanone

[0315] 2-Bromo-5-nitrobenzoic acid 11a (1.0 g, 4.06 mmol, commercially available) and (R)-3-pyrrolidinol 11b (0.42 g, 4.88 mmol, commercially available) were dissolved in N,N-dimethylformamide (10 mL). N,N-diisopropylethylamine (1.58 g, 12.19 mmol) and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (2.32 g, 6.10 mmol) were added sequentially, and the mixture was stirred at room temperature for 4 hours. A mixed solvent of dichloromethane and methanol (33 mL, V:V = 10:1) was added to dilute the mixture, and the mixture was washed three times with water (30 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting residue was separated and purified by silica gel column chromatography (eluent: System B) to give (R)-(2-bromo-5-nitrophenyl)(3-hydroxypyrrolidin-1-yl)methanone 11c (1.07 g) in an 83% yield.

[0316] MS m / z(ESI):315.0[M+1]

[0317] Step 2

[0318] (R)-1-(2-Bromo-5-nitrobenzyl)pyrrolidin-3-ol

[0319] Dissolve (R)-(2-bromo-5-nitrophenyl)(3-hydroxypyrrolidin-1-yl)methanone 11c (1.0 g, 3.17 mmol) in tetrahydrofuran (5 mL). Add a 1.0 M solution of borane in tetrahydrofuran (9.5 mL) at room temperature. Heat to 65°C and stir for 8 hours. Cool, then slowly add concentrated hydrochloric acid dropwise in an ice bath until no bubbles form. Stir at 65°C for 1 hour. The reaction mixture was cooled and alkalized to a weakly alkaline pH by adding 20% ​​aqueous sodium hydroxide solution dropwise under an ice bath. The mixture was then extracted with a mixed solvent of dichloromethane and methanol (V:V = 10:1) (30 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was separated and purified by silica gel column chromatography (eluent: System B) to give (R)-1-(2-bromo-5-nitrobenzyl)pyrrolidin-3-ol 11d (0.65 g) in a yield of 68%.

[0320] MS m / z(ESI):301.0[M+1]

[0321] Step 3

[0322] (R)-1-(2-(3,6-dihydro-2H-pyran-4-yl)-5-nitrobenzyl)pyrrolidin-3-ol

[0323] (R)-1-(2-Bromo-5-nitrobenzyl)pyrrolidin-3-ol 11d (0.60 g, 1.99 mmol) and 2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 11e (0.50 g, 2.39 mmol, commercially available) were dissolved in 1,4-dioxane (15 mL), and 1,1-bis(diphenylphosphino)dichloropalladium iron (0.15 g, 0.20 mmol), potassium carbonate (0.8 The product was prepared by adding 1-(2-(3,6-dihydro-2H-pyran-4-yl)-5-nitrobenzyl)pyrrolidin-3-ol 11f (0.6 g) into the product. The product was reacted for 6 hours and then cooled to room temperature. The product was filtered under reduced pressure and the filter cake was washed with a mixed solvent of dichloromethane and methanol (33 mL, V:V=10:1). The organic phase was concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent: System B) to give (R)-1-(2-(3,6-dihydro-2H-pyran-4-yl)-5-nitrobenzyl)pyrrolidin-3-ol 11f (0.6 g) in a yield of 99%.

[0324] MS m / z(ESI):305.1[M+1]

[0325] Step 4

[0326] (R)-1-(5-amino-2-(tetrahydro-2H-pyran-4-yl)benzyl)pyrrolidin-3-ol

[0327] (R)-1-(2-(3,6-dihydro-2H-pyran-4-yl)-5-nitrobenzyl)pyrrolidin-3-ol 11f (0.55 g, 1.81 mmol) was dissolved in tetrahydrofuran (10 mL) and palladium hydroxide on carbon (20%, 0.13 g) was added. The mixture was reacted at room temperature under a hydrogen atmosphere for 48 hours. After completion of the reaction, the reaction solution was filtered through celite, and the filter cake was washed with a mixture of dichloromethane and methanol (33 mL, V:V = 10:1). The organic phase was concentrated under reduced pressure, and the resulting residue was isolated and purified by silica gel column chromatography (eluent: System B) to obtain (R)-1-(5-amino-2-(tetrahydro-2H-pyran-4-yl)benzyl)pyrrolidin-3-ol 11g (0.37 g) in a 74% yield.

[0328] MS m / z(ESI):277.2[M+1]

[0329] Step 5

[0330] (R)-1-(5-((5-chloro-8-(4-methylpyridin-3-yl)quinazolin-2-yl)amino)-2-(tetrahydro-2H-pyran-4-yl)benzyl)pyrrolidin-3-ol

[0331] 2,5-Dichloro-8-(4-methylpyridin-3-yl)quinazoline 6b (0.44 g, 1.52 mmol) and (R)-1-(5-amino-2-(tetrahydro-2H-pyran-4-yl)benzyl)pyrrolidin-3-ol 11 g (0.35 g, 1.27 mmol) were dissolved in tert-butanol (10 mL). Trifluoroacetic acid (0.14 g, 1.27 mmol) was added, and the reaction mixture was heated to 100°C for 6 hours. After cooling and concentration under reduced pressure, the resulting residue was isolated and purified by silica gel column chromatography (eluent: System B) to afford (R)-1-(5-((5-chloro-8-(4-methylpyridin-3-yl)quinazolin-2-yl)amino)-2-(tetrahydro-2H-pyran-4-yl)benzyl)pyrrolidin-3-ol 11h (0.25 g) in a 37% yield.

[0332] MS m / z(ESI):530.3[M+1]

[0333] Step 6

[0334] tert-Butyl (R)-(2-((3-((3-hydroxypyrrolidin-1-yl)methyl)-4-(tetrahydro-2H-pyran-4-yl)phenyl)amino)-8-(4-methylpyridin-3-yl)quinazolin-5-yl)carbamate

[0335] (R)-1-(5-((5-chloro-8-(4-methylpyridin-3-yl)quinazolin-2-yl)amino)-2-(tetrahydro-2H-pyran-4-yl)benzyl)pyrrolidin-3-ol 11h (0.23 g, 0.43 mmol) and tert-butyl carbamate (0.75 g, 6.37 mmol) were dissolved in 1,4-dioxane (10 mL), and tris(dibenzylideneacetone)dipalladium (39 mg, 0.042 mmol), 2-(dicyclohexylphosphine)3,6-dimethoxy-2',4',6'-triisopropyl-1,1'-biphenyl (46 mg, 0.085 mmol), cesium carbonate (0.41 g, 1.27 mmol) and The reaction mixture was heated to 90°C for 6 hours, then cooled, filtered, and washed with a mixed solvent of dichloromethane and methanol (33 mL, V:V = 10:1). The organic phase was concentrated under reduced pressure, and the residue was separated and purified by silica gel column chromatography (eluent: System B) to give tert-butyl (R)-(2-((3-((3-hydroxypyrrolidin-1-yl)methyl)-4-(tetrahydro-2H-pyran-4-yl)phenyl)amino)-8-(4-methylpyridin-3-yl)quinazolin-5-yl)carbamate 11i (120 mg) in a yield of 46%.

[0336] MS m / z(ESI):611.3[M+1]

[0337] Step 7

[0338] (R)-1-(5-((5-amino-8-(4-methylpyridin-3-yl)quinazolin-2-yl)amino)-2-(tetrahydro-2H-pyran-4-yl)benzyl)pyrrolidin-3-ol

[0339] Tert-butyl (R)-(2-((3-((3-hydroxypyrrolidin-1-yl)methyl)-4-(tetrahydro-2H-pyran-4-yl)phenyl)amino)-8-(4-methylpyridin-3-yl)quinazolin-5-yl)carbamate 11i (0.11 g, 0.18 mmol) was dissolved in dichloromethane (10 mL), and trifluoroacetic acid (1.0 mL) was added dropwise, and the reaction was carried out at room temperature for 3 hours. The reaction solution was diluted with water and neutralized with saturated sodium bicarbonate solution until the solution became alkaline. The solution was extracted with a mixed solvent of dichloromethane and methanol (V:V=10:1) (30 mL×3), washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The resulting residue was separated and purified by silica gel column chromatography (eluent: System B) to give (R)-1-(5-((5-amino-8-(4-methylpyridin-3-yl)quinazolin-2-yl)amino)-2-(tetrahydro-2H-pyran-4-yl)benzyl)pyrrolidin-3-ol 11 (50 mg) in a yield of 54%.

[0340] MS m / z(ESI):511.3[M+1]

[0341] 1 H NMR (400MHz, DMSO-d6) δ9.55 (s, 1H), 9.47 (s, 1H), 8.46 (d, J = 4.8Hz, 1H), 8.35 (s, 1H) ),7.56(s,1H),7.46(d,J=8.4Hz,1H),7.33-7.38(m,2H),6.94(d,J=8.0Hz,1H),6.5 4(d,J=8.0Hz,1H),6.45(s,2H),4.62(s,1H),4.16(m,1H),3.89-3.94(m,2H),3.35- 3.43(m,4H),3.00-3.08(m,1H),2.09(s,3H),1.90-1.99(m,2H),1.46-1.64(m,6H).

[0342] Example 12 was synthesized according to the synthesis method of Example 11 of the present invention. The spectrum parameters of Example 12 are shown in the following table:

[0343] Biological evaluation

[0344] Test Example 1: Test of the Inhibitory Activity of the Compounds of the Invention on HPK1 Kinase

[0345] The following method is used to determine the degree of inhibition of the compounds of the present invention on the activity of recombinant human HPK1 kinase under in vitro conditions. This method uses Promega's ADP-Glo TM Kinase Assay Kit (Cat. No. V9102). This kit is a luminescent kinase assay used to measure the amount of ADP produced by the kinase reaction. ADP levels are positively correlated with kinase activity, and measuring ADP levels reflects the inhibitory effect of a compound on HPK1 kinase activity. For detailed experimental procedures, please refer to the kit instructions.

[0346] The experimental procedure is briefly described as follows: the test compound was first dissolved in DMSO to prepare a stock solution. A buffer solution (20 mM MgCl2, 50 μM DTT, 0.1 mg / ml BSA, 40 mM Tris, pH 7.4) was then prepared according to the buffer recipe provided in the reagent manual. This buffer was then used for serial dilutions, with the final concentration of the test compound in the reaction system ranging from 1000 nM to 0.02 nM. Reactions were performed in a 384-well microplate. Compounds and recombinant human HPK1 protein (final concentration 1 ng / μL, purchased from Signalchem, Cat. No. M23-11G-10) were first added to the wells and incubated at room temperature for 5 minutes. ATP solution (final concentration 10 μM) and the substrate MBP (final concentration 0.2 μg / μL, purchased from Signalchem, Cat. No. M42-51N) were then added to the reaction solution and incubated at room temperature for 60 minutes with shaking. Then, 5 μL of ADP-Glo ​​Reagent was added to the reaction system and incubated at room temperature for 40 minutes. Then, 10 μL of Kinase Detection Reagent was added to the reaction system and incubated at room temperature for 30 minutes. After the incubation, the chemiluminescence intensity of each well was measured in the luminescence mode of the microplate reader. The percentage inhibition rate of the compound at each concentration was calculated by comparing the luminescence intensity ratio with that of the control group (0.1% DMSO), and the nonlinear regression analysis of the compound concentration-inhibition rate was performed using GraphPad Prism 5 software to obtain the IC value of the compound. 50 Values, see Table 1.

[0347] Table 1 IC50 data of the compounds of the present invention for inhibiting HPK1 kinase activity

[0348] It can be seen from Table 1 that the compounds of the present invention have good inhibitory activity against HPK1 kinase.

[0349] Test Example 2: Determination of the inhibitory activity of the compounds of the present invention on p-SLP76 S376 in Jurkat cells

[0350] The following method was used to determine the inhibitory activity of the compounds of the present invention against p-SLP76 S376 in Jurkat cells. This method utilizes the Cisbio Phospho-SLP-76 (Ser376) Cellular Kit (Cat. No. 63ADK076PEG). For detailed experimental procedures, refer to the kit instructions. Jurkat cells were purchased from the Cell Resource Center of the Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences.

[0351] The experimental procedure is briefly described as follows: Jurkat cells were cultured in RPMI 1640 complete medium (purchased from Biological Industries, Cat. No. 01-100-1A) supplemented with 10% fetal bovine serum, 100 U penicillin, 100 μg / mL streptomycin, and 1 mM sodium pyruvate. 8 μL of Jurkat cells (100,000 cells per well) were plated in a 384-well plate and incubated at 37°C in a 5% CO2 incubator. Test compounds were dissolved in DMSO to a 10 mM stock solution and subsequently diluted in RPMI 1640 complete medium. 2 μL of RPMI 1640 complete medium containing the corresponding test compound concentration was added to each well. The final concentration of the test compound in the system ranged from 10,000 nM to 0.01 nM. The cells were incubated in a cell culture incubator for 1 hour. Subsequently, 2 μL of anti-human CD3 (5 μg / mL, purchased from BioLegend, Cat. No. 317302) was added and the cells were incubated in a cell culture incubator for 30 minutes. Following this, 4 μL of lysis buffer was added for 45 minutes. Finally, 4 μL of Phospho-SLP-76 cryptate antibody and Phospho-SLP-76d2 antibody were added and incubated overnight at room temperature. Fluorescence intensities at emission wavelengths of 620 nM and 665 nM were measured on a microplate reader in TF-FRET mode under an excitation wavelength of 304 nM. The 665 / 620 fluorescence intensity ratio was calculated for each well. The percentage inhibition rate of the test compound at each concentration was calculated by comparing the fluorescence intensity ratio with that of the control group (0.1% DMSO), and the IC value of the compound was obtained by nonlinear regression analysis using the test compound concentration logarithm-inhibition rate using GraphPad Prism 5 software. 50 Values ​​are shown in Table 2.

[0352] Table 2 IC of the inhibitory activity of the compounds of the present invention on p-SLP76 S376 in Jurkat cells 50 data

[0353] It can be seen from Table 2 that the compounds of the present invention have a good inhibitory effect on p-SLP76 S376 in Jurkat cells.

[0354] Test Example 3: Determination of the Activation Ability of the Compounds of the Invention on IL2 Release in Jurkat Cells

[0355] The following method is used to determine the ability of the compounds of the present invention to activate IL2 release in Jurkat cells. This method uses the Human IL2 kit from Cisbio The kit (Cat. No. 62HIL02PEG) was used. For detailed experimental procedures, please refer to the kit instructions. Jurkat cells were purchased from the Cell Resource Center of the Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences.

[0356] The experimental procedure is briefly described as follows: Jurkat cells were cultured in RPMI 1640 complete medium (purchased from Biological Industries, Cat. No. 01-100-1A) supplemented with 10% fetal bovine serum, 100 U penicillin, 100 μg / mL streptomycin, and 1 mM sodium pyruvate. 8 μL of Jurkat cells (50,000 cells per well) were plated in a 384-well plate and incubated at 37°C in a 5% CO2 incubator. The test compound was dissolved in DMSO to prepare a 10 mM stock solution, which was then diluted using RPMI 1640 complete medium. 4 uL of RPMI 1640 complete medium containing the corresponding concentration of the test compound was added to each well. The final concentration of the test compound in the system ranged from 10,000 nM to 41 nM, and the cells were cultured in a cell culture incubator for 30 minutes. Subsequently, 4 ul of Anti-human CD3 (5 ug / ml, purchased from BioLegend, Catalog No. 317302) and Anti-human CD28 (5 ug / ml, purchased from BioLegend, Catalog No. 302902) were added, and the cells were cultured in a cell culture incubator for 4 hours. Subsequently, 4 uL of IL2Eu Cryptate Antibody and IL2d2 Antibody were added, and the cells were incubated at room temperature overnight. The fluorescence intensity of each well at 620 nM and 665 nM emission wavelengths was measured on a microplate reader in TF-FRET mode at an excitation wavelength of 304 nM. The fluorescence intensity ratio of 665 / 620 was calculated for each well. For data analysis, the control group (0.1% DMSO) was set to 0% activation, and the 3 uM positive control (3 uM 1787) was set to 100% activation. The activation ratio of the test compound at each concentration was calculated, and nonlinear regression analysis was performed using GraphPad Prism 5 software using the logarithm of the test compound concentration-activation ratio to obtain the EC value of the compound. 50 Values ​​are shown in Table 3.

[0357] Table 3 Activation ability of the compounds of the present invention on IL2 release in Jurkat cells EC 50 data

[0358] It can be concluded from Table 3 that the compounds of the present invention have a good ability to activate the release of IL2 in Jurkat cells.

Claims

1. A compound represented by general formula (I) or its stereoisomers, tautomers or pharmaceutically acceptable salts: in: Ring A selects the following groups: X is selected from CR a or N; R a 、R b are the same or different and are each independently selected from a hydrogen atom, a halogen, a hydroxyl, an amino, an alkyl, an alkoxy or a cyano group; wherein the alkyl or alkoxy group is optionally further substituted by one or more substituents selected from a halogen, a hydroxyl, a cyano group, an alkyl or an alkoxy group; R 3 The same or different, each independently selected from hydrogen atom, hydroxyl, halogen, alkyl, cyano, alkoxy, cycloalkyl, heterocyclic group or -NR c R d wherein the alkyl, alkoxy, cycloalkyl or heterocyclic group is optionally further substituted with one or more halogen, amino, hydroxy, cyano, alkyl or alkoxy substituents; R c 、R d The same or different, each independently selected from hydrogen atom, alkyl, cycloalkyl, heterocyclic group, -C(O)R 4 or -S(O)2R 4 ; wherein the alkyl, cycloalkyl or heterocyclic group is optionally further substituted by one or more substituents selected from halogen, amino, hydroxy, cyano, alkyl or alkoxy; L is selected from a bond, -C(O)-, -OC(O)-, -SC(O)-, -CH2C(O)- or -NR e C(O)-; R e is selected from a hydrogen atom or an alkyl group; Ring B is selected from a fused ring, an aryl group, a heteroaryl group, a cycloalkyl group or a heterocyclyl group; R 1 are the same or different and are each independently selected from alkyl, cycloalkyl, aryl, heteroaryl, heterocyclic or fused ring, wherein the alkyl, cycloalkyl, aryl, heteroaryl, heterocyclic or fused ring is optionally further substituted by one or more R A replaced by; Each R A The same or different, each independently selected from alkyl, halogen, nitro, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -OR 4 、-C(O)R 4 、-C(O)OR 4 、-NHC(O)R 4 、-NHC(O)OR 4 、-NR 5 R 6 、-C(O)NR 5 R 6 、-CH2NHC(O)OR 4 、-CH2NR 5 R 6 、-P(O)R 5 R 6 、-S(O) r NR 5 R 6 or -S(O) r R 4 wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl or heteroaryl is optionally further substituted by one or more groups selected from alkyl, halogen, nitro, cyano, cycloalkyl, heterocyclic, aryl, heteroaryl, =O, -OR 4 、-C(O)R 4 、-C(O)OR 4 、-NHC(O)R 4 、-NHC(O)OR 4 、-NR 5 R 6 、-C(O)NR 5 R 6 、-CH2NHC(O)OR 4 、-CH2NR 5 R 6 or -S(O) r R 4 substituted by a substituent; Or, two R A Together with the carbon atom to which it is attached, it forms a -C(=O)-; R 2 The same or different, each independently selected from hydrogen atom, alkyl, halogen, nitro, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl, heteroaryl, -OR 4 、-C(O)R 4 、-C(O)OR 4 、-NHC(O)R 4 、-NHC(O)OR 4 、-NR 5 R 6 、-C(O)NR 5 R 6 、-CH2NHC(O)OR 4 、-CH2NR 5 R 6 or -S(O) r R 4 wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally further substituted by one or more R B replaced by; Or, two R 2 Together with the carbon atom to which it is attached, it forms a -C(=O)-; Each R B The same or different, each independently selected from alkyl, halogen, nitro, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -OR 4 、-C(O)R 4 、-C(O)OR 4 、-NHC(O)R 4 、-NHC(O)OR 4 、-NR 5 R 6 、-C(O)NR 5 R 6 、-CH2NHC(O)OR 4 、-CH2NR 5 R 6 or -S(O) r R 4 wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl or heteroaryl is optionally further substituted by one or more groups selected from alkyl, halogen, nitro, cyano, cycloalkyl, heterocyclic, aryl, heteroaryl, =O, -OR 4 、-C(O)R 4 、-C(O)OR 4 、-NHC(O)R 4 、-NHC(O)OR 4 、-NR 5 R 6 、-C(O)NR 5 R 6 、-CH2NHC(O)OR 4 、-CH2NR 5 R 6 or -S(O) r R 4 substituted by a substituent; Or, two R B Together with the carbon atom to which it is attached, it forms a -C(=O)-; R 4 Each is independently selected from a hydrogen atom, an alkyl group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein the alkyl group, the cycloalkyl group, the heterocyclic group, the aryl group or the heteroaryl group is optionally further substituted by one or more hydroxyl groups, halogen groups, nitro groups, cyano groups, alkyl groups, alkoxy groups, haloalkyl groups, haloalkoxy groups, cycloalkyl groups, heterocyclic groups, aryl groups, heteroaryl groups, =O, -C(O)R 7 、-C(O)OR 7 、-OC(O)R 7 、-NR 8 R 9 、-C(O)NR 8 R 9 、-SO2NR 8 R 9 or -NR 8 C(O)R 9 substituted by a substituent; R 5 and R 6 Each is independently selected from hydrogen, hydroxy, halogen, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally further substituted by one or more selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, =O, -C(O)R 7 、-C(O)OR 7 、-OC(O)R 7 、-NR 8 R 9 、-C(O)NR 8 R 9 、-SO2NR 8 R 9 or -NR 8 C(O)R 9 substituted by a substituent; Or, R 5 and R 6 Together with the atoms to which they are attached, they form a 4- to 8-membered heterocyclic group, wherein the 4- to 8-membered heterocyclic group contains one or more N, O or S(O) r , and the 4- to 8-membered heterocyclic group is optionally further substituted by one or more selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, =O, -C(O)R 7 、-C(O)OR 7 、-OC(O)R 7 、-NR 8 R 9 、-C(O)NR 8 R 9 、-SO2NR 8 R 9 or -NR 8 C(O)R 9 substituted by a substituent; R 7 、R 8 and R 9 Each is independently selected from a hydrogen atom, an alkyl group, an amino group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein the alkyl group, the cycloalkyl group, the heterocyclic group, the aryl group or the heteroaryl group is optionally further substituted with one or more substituents selected from a hydroxyl group, a halogen group, a nitro group, an amino group, a cyano group, an alkyl group, an alkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group, a heteroaryl group, a carboxyl group or a carboxylate group; m is selected from 0, 1, 2, 3, 4 or 5; and r is 0, 1, or 2.

2. The compound according to claim 1, or its stereoisomer, tautomer, or pharmaceutically acceptable salt, which is a compound or its stereoisomer, tautomer, or pharmaceutically acceptable salt according to general formula (II), (III), (IV), or (V): in: Ring B, L, R 1 ~R 3 、R a 、R b and m are as defined in claim 1.

3. The compound according to claim 1 or 2, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein R 1 is selected from aryl, heteroaryl, heterocyclic or fused ring, wherein the aryl, heteroaryl, heterocyclic or fused ring is optionally further substituted by one or more selected from alkyl, halogen, hydroxy, amino, hydroxyalkyl, =O, -P(O)R 5 R 6 、-S(O) r NR 5 R 6 or -S(O) r R 4 substituted by a substituent; The R 4 、R 5 、R 6 are each independently selected from a hydrogen atom or an alkyl group; r is 0, 1 or 2.

4. The compound according to claim 3, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein R 1 Selected from the following groups:

5. The compound according to claim 1 or 2, or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, wherein L is selected from a bond.

6. The compound according to claim 1 or 2, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein L is selected from -C(O)-, -OC(O)-, or -NR e C(O)-; wherein the R e is selected from a hydrogen atom or a methyl group.

7. The compound according to claim 1 or 2, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein ring B is selected from the following groups:

8. The compound according to claim 1 or 2, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein R 2 the same or different, each independently selected from a hydrogen atom, an alkyl group, a halogen group, a cyano group, an alkoxy group, a cycloalkyl group, a heterocyclic group or -C(O)NR 5 R 6 wherein the alkyl, alkoxy, cycloalkyl or heterocyclic group is optionally further substituted by one or more R B replaced by; Or, two R 2 Together with the carbon atom to which it is attached, it forms a -C(=O)-; R B The same or different, each independently selected from alkyl, halogen, hydroxy, cyano, alkoxy, cycloalkyl, heterocyclyl or -C(O)NR 5 R 6 wherein the alkyl, alkoxy, cycloalkyl or heterocyclic group is optionally further substituted by one or more substituents selected from alkyl, halogen, cyano, hydroxy, amino, alkoxy, haloalkyl, hydroxyalkyl or haloalkoxy; The R 5 、R 6 are each independently selected from a hydrogen atom or an alkyl group.

9. The compound according to any one of claims 6 to 8, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein Selected from the following groups:

10. The compound according to claim 1 or 2, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein R 3 is selected from amino or halogen.

11. The compound according to any one of claims 1 to 10, or its stereoisomer, tautomer, or pharmaceutically acceptable salt, wherein the compound is:

12. A pharmaceutical composition comprising an effective dose of the compound according to any one of claims 1 to 11, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, excipient, or a combination thereof.

13. Use of the compound according to any one of claims 1 to 11, or its stereoisomer, tautomer, or pharmaceutically acceptable salt, or the pharmaceutical composition according to claim 12, in the preparation of an HPK1 inhibitor.

14. Use of the compound according to any one of claims 1 to 11, or its stereoisomers, tautomers, or pharmaceutically acceptable salts, or the pharmaceutical composition according to claim 12, in the preparation of a medicament for treating a disease mediated by HPK1, wherein the disease mediated by HPK1 is preferably inflammation, an autoimmune disease, or a tumor, wherein the autoimmune disease is preferably systemic lupus erythematosus or psoriasis; and wherein the tumor is preferably a malignant hematological tumor or a malignant solid tumor.

15. The method of claim 14, wherein the tumor is selected from the group consisting of acute myeloid leukemia, bladder cancer, colon cancer, rectal cancer, pancreatic cancer, lung cancer, small cell lung cancer, non-small cell lung cancer, lymphoma, blastoma, retinoblastoma, sarcoma, prostate cancer, bile duct cancer, esophageal cancer, gastric cancer, liver cancer, glioma, cervical cancer, ovarian cancer, head and neck cancer, and multiple myeloma.

16. Use of the compound according to any one of claims 1 to 11, or its stereoisomers, tautomers, or pharmaceutically acceptable salts, or the pharmaceutical composition according to claim 12, in the preparation of a medicament for treating inflammation, autoimmune diseases, or tumors, wherein the autoimmune disease is preferably systemic lupus erythematosus or psoriasis; wherein the tumor is preferably a malignant hematological tumor or a malignant solid tumor.

17. The method of claim 16, wherein the tumor is selected from the group consisting of acute myeloid leukemia, urothelial carcinoma, colon cancer, rectal cancer, pancreatic cancer, lung cancer, small cell lung cancer, non-small cell lung cancer, lymphoma, blastoma, retinoblastoma, sarcoma, prostate cancer, bile duct cancer, esophageal cancer, gastric cancer, liver cancer, glioma, cervical cancer, ovarian cancer, head and neck cancer, and multiple myeloma.